6-K 1 caq42024.htm 6-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 6-K
_________________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 5, 2025
_________________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
_________________________
Novo Allé
DK-2880 Bagsværd
Denmark
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F x Form 40-F o
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________

Financial report for the period 1 January 2024 to 31 December 2024
5 February 2025
Novo Nordisk's sales increased by 25% in Danish kroner and by 26% at constant exchange rates to DKK 290.4 billion in 2024
•Operating profit increased by 25% in Danish kroner a nd by 26% at co nstant exchange rates (CER) to DKK 128.3 billion. Operating profit was positively impacted by gross-to-net sales adjustments in the US and negatively impacted by impairment losses.
•Sales in North America Operations increased by 30% in Danish kroner (30% at CER). Sales in International Operations increased by 17% in Danish kroner (19% at CER).
•Sales within Diabetes and Obesity care increased by 26% in Danish kroner to DKK 271.8 billion (27% at CER), mainly driven by GLP-1 diabetes sales growth of 21% in Danish kroner (22% at CER) and Obesity care growing by 56% in Danish kroner to DKK 65.1 billion (57% at CER). Rare disease sales increased by 9% in both Danish kroner and at CER.
•Within R&D, CagriSema demonstrated superior weight loss in adults with obesity or overweight in the REDEFINE 1 trial, where people treated with CagriSema achieved a superior weight loss of 22.7%. Further, semaglutide 7.2 mg achieved 20.7% weight loss in the STEP UP obesity trial. Lastly, a phase 1b/2a with injectable amycretin in people with overweight or obesity was successfully completed.
•In December 2024, Novo Nordisk announced that the acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings was completed.
•For the 2025 outlook, sales growth is expected to be 16-24% at CER, and operating profit growth is expected to be 19-27% at CER. Sales and operating profit growth reported in Danish kroner is expected to be 3 and 5 percentage points higher than at CER, respectively.
•At the Annual General Meeting on 27 March 2025, the Board of Directors will propose a final dividend of DKK 7.90 for 2024 per share. The expected total dividend for 2024 will increase 21% to DKK 11.40 per share, of which DKK 3.50 was paid as interim dividend in August 2024.

PROFIT AND LOSS | 2024 | 2023 | Growth as reported | Growth at CER*
DKK million |  |  |  |
Net sales | 290,403 |  | 232,261 |  | 25 | % | 26 | %
Operating profit | 128,339 |  | 102,574 |  | 25 | % | 26 | %
Net profit | 100,988 |  | 83,683 |  | 21 | % | N/A
Diluted earnings per share (in DKK) | 22.63 |  | 18.62 |  | 22 | % | N/A
* CER: Constant exchange rates (average 2023). |  |  |  |

Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the performance in 2024, where 26% sales growth reflects that more than 45 million people are now benefiting from our treatments. Further, we completed the acquisition of the three Catalent sites, and during the year, we progressed our R&D pipeline, including obesity projects such as CagriSema and amycretin. In 2025, we will continue our focus on commercial execution, on the progression of our early and late-stage R&D pipeline and on the expansion of our production capacity."
On 5 February 2025 at 13.00 CET, corresponding to 07.00 am EST, an earnings call will be held. Investors will be able to listen in via a link on novonordisk.com, which can be found under 'Investors' (the contents of the company's website do not form a part of this Form 6-K).

Novo Nordisk A/S Investor Relations | Novo Alle 1 2880 Bagsværd Denmark | Telephone: +45 4444 8888 www.novonordisk.com | CVR Number: 24 25 67 90
|  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 2 of 35

STRATEGIC ASPIRATIONS
STRATEGIC ASPIRATIONS 2025
The strategic aspirations are objectives that Novo Nordisk intends to work towards and are not a projection of Novo Nordisk's financial outlook or expected growth. Novo Nordisk intends to describe how its activities develop in relation to each of the four dimensions on an ongoing basis.
Performance highlights for 2024 (blue indicates fourth quarter developments)

PERFORMANCE HIGHLIGHTS |  |  |  |  |
Purpose and sustainability (ESG) |  |  |  |
Progress towards zero environmental impact: –Overall CO 2 e emissions (scope 1, 2 and full scope 3) increased by 23% compared to 2023 Adding value to society: –Medical treatment provided to 43.0 million people living with diabetes and 2.2 million people living with obesity –Reached more than 64,000 children in the Changing Diabetes® in Children programme |  | Being recognised as a sustainable employer: –Share of women in senior leadership positions has increased by 0.7 percentage point to 42% compared to 2023 Sustainable supply chain: –Acquisition of Catalent by Novo Holdings and the related acquisition by Novo Nordisk of three manufacturing sites from Novo Holdings completed |  |
Innovation and therapeutic focus |  |  |  |
Further raise innovation bar for Diabetes treatment: –Awiqli® approved in the EU, Japan and China –Complete Response Letter received for insulin icodec in the US –Successful completion of phase 3a programme with IcoSema –US approval and positive EU opinion for an update of the Ozempic® label based on the FLOW kidney trial –Submission of the SOUL cardiovascular outcomes trial and STRIDE functional outcomes trial in the US and EU Develop superior treatment solutions for Obesity: –Phase 2 trial initiated with once-weekly GIP/GLP-1 dual agonist –Phase 2a trial with monlunabant completed –CagriSema demonstrated superior weight loss in the REDEFINE 1 trial –Phase 3b trials, STEP UP and STEP UP T2D, with semaglutide 7.2 mg successfully completed –Phase 1b/2a trial with injectable amycretin successfully completed –Phase 1 trial with a tri-agonist (Triple) initiated |  | Strengthen and progress Rare disease pipeline: –Phase 3a trial, FRONTIER 2, with Mim8 successfully completed in people with haemophilia A –Successful completion of the phase 2 part (interim) of the etavopivat HIBISCUS phase 2/3 trial –Alhemo® (Concizumab) approved in the US and EU for the treatment of haemophilia A and B with inhibitors –Alhemo® submitted in the EU for the treatment of haemophilia A and B without inhibitors Establish presence in Cardiovascular & Emerging Therapy Areas: –Agreement to acquire Cardior Pharmaceuticals and lead asset CDR132L in phase 2 development for treatment of heart failure –Phase 3 development initiated with ziltivekimab in HFpEF and AMI –Phase 3 trial CLARION-CKD trial stopped as ocedurenone failed to meet primary endpoint –Successful completion of part I of phase 3 trial ESSENCE with semaglutide 2.4 mg in MASH |  |
Commercial execution |  |  |  |
Strengthen diabetes leadership to more than one-third: –Diabetes value market share remained unchanged at 33.7% (MAT) |  | More than DKK 25 billion in Obesity care sales by 2025: –Obesity care sales increased by 57% (CER) to DKK 65.1 billion Secure a sustained growth outlook for Rare Disease: –Rare disease sales increased by 9% (CER) to DKK 18.6 billion |  |
Financials |  |  |  |
Deliver solid sales and operating profit growth: –Sales growth of 26% (CER) –Operating profit growth of 26% (CER), negatively impacted by impairment losses related to intangible assets |  | Drive operational efficiencies: –Operational leverage reflecting sales growth, when excluding impairment losses Enable attractive capital allocation to shareholders: –Free cash flow of DKK (14.7) billion, negatively impacted by the Catalent transaction –DKK 64.3 billion returned to shareholders |  |

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 3 of 35

PERFORMANCE HIGHLIGHTS
FINANCIAL HIGHLIGHTS FOR 2024

PROFIT AND LOSS | 2024 |  | 2023 | 2022 | 2021 | 2020 |  |  |  |  | % change 2024 to 2023 |  | % change 2024 to 2023 at CER¹
(Amounts are in DKK million, except for earnings per share) |  |  |  |  |  |  |  |  |  |  |  |  |  |
Net sales | 290,403 |  | 232,261 | 176,954 | 140,800 | 126,946 |  |  |  |  | 25 | % |  | 26 | % |
Gross profit | 245,881 |  | 196,496 | 148,506 | 117,142 | 106,014 |  |  |  |  | 25 | % |  | 26 | % |
Gross margin | 84.7% |  | 84.6% | 83.9% | 83.2% | 83.5% |  |  |  |  |  |  |  |
Sales and distribution costs | (62,101) |  | (56,743) | (46,217) | (37,008) | (32,928) |  |  |  |  | 9 | % |  | 10 | % |
Percentage of sales | 21.4% |  | 24.4% | 26.1% | 26.3% | 25.9% |  |  |  |  |  |  |  |
Research and development costs | (48,062) |  | (32,443) | (24,047) | (17,772) | (15,462) |  |  |  |  | 48 | % |  | 48 | % |
Percentage of sales | 16.6% |  | 14.0% | 13.6% | 12.6% | 12.2% |  |  |  |  |  |  |  |
Administrative costs | (5,276) |  | (4,855) | (4,467) | (4,050) | (3,958) |  |  |  |  | 9 | % |  | 9 | % |
Percentage of sales | 1.8% |  | 2.1% | 2.5% | 2.9% | 3.1% |  |  |  |  |  |  |  |
Other operating income and expenses | (2,103) |  | 119 | 1,034 | 332 | 460 |  |  |  |  | N/A |  | N/A |
Operating profit (EBIT) | 128,339 |  | 102,574 | 74,809 | 58,644 | 54,126 |  |  |  |  | 25 | % |  | 26 | % |
Operating margin | 44.2% |  | 44.2% | 42.3% | 41.7% | 42.6% |  |  |  |  |  |  |  |
Financial items (net) | (1,148) |  | 2,100 | (5,747) | 436 | (996) |  |  |  |  | N/A |  | N/A |
Profit before income taxes | 127,191 |  | 104,674 | 69,062 | 59,080 | 53,130 |  |  |  |  | 22 | % |  | N/A |
Income taxes | (26,203) |  | (20,991) | (13,537) | (11,323) | (10,992) |  |  |  |  | 25 | % |  | N/A |
Effective tax rate | 20.6% |  | 20.1% | 19.6% | 19.2% | 20.7% |  |  |  |  |  |  |  |
Net profit | 100,988 |  | 83,683 | 55,525 | 47,757 | 42,138 |  |  |  |  | 21 | % |  | N/A |
Net profit margin | 34.8% |  | 36.0% | 31.4% | 33.9% | 33.2% |  |  |  |  |  |  |  |
OTHER KEY NUMBERS |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation, amortisation and impairment losses | 19,107 |  | 9,413 | 7,362 | 6,025 | 5,753 |  |  |  |  | 103 | % |  | N/A |
Capital expenditure (PP&E) | 47,164 |  | 25,806 | 12,146 | 6,335 | 5,825 |  |  |  |  | 83 | % |  | N/A |
Net cash generated from operating activities | 120,968 |  | 108,908 | 78,887 | 55,000 | 51,951 |  |  |  |  | 11 | % |  | N/A |
EBITDA 1) | 147,446 |  | 111,987 | 82,171 | 64,669 | 59,879 |  |  |  |  | 32 | % |  | 33 | % |
Free cash flow 1) | (14,707) |  | 68,326 | 57,362 | 29,319 | 28,565 |  |  |  |  | (122 | %) |  | N/A |
Total assets | 465,795 |  | 314,486 | 241,257 | 194,508 | 144,922 |  |  |  |  | 48 | % |  | N/A |
Equity | 143,486 |  | 106,561 | 83,486 | 70,746 | 63,325 |  |  |  |  | 35 | % |  | N/A |
Equity ratio | 30.8% |  | 33.9% | 34.6% | 36.4% | 43.7% |  |  |  |  |  |  |  |
Diluted earnings per share / ADR (in DKK) | 22.63 |  | 18.62 | 12.22 | 10.37 | 9.01 |  |  |  |  | 22 | % |  | N/A |
Total dividend per share 2) | 11.40 |  | 9.40 | 6.20 | 5.20 | 4.55 |  |  |  |  | 21 | % |  | N/A |
Payout ratio 3) | 50.2% |  | 50.2% | 50.3% | 49.6% | 50.0% |  |  |  |  |  |  |  |
1) See appendix 7: Non-IFRS financial measures (additional information). |
2) Total dividend for the financial year 2024 including proposed final dividend of DKK 7.90 per share and interim dividend paid in August 2024 of DKK 3.50 per share. |
3) Total dividend for the year as a percentage of net profit. |  |  |

The Board of Directors and Executive Management have considered and approved the Annual Report 2024 of Novo Nordisk A/S, including the audited consolidated financial statements. The Board of Directors and Executive Management have also approved this financial report containing condensed financial information for 2024. The condensed financial statements in this financial report have been prepared in accordance with the recognition and measurement requirements of the IFRS Accounting Standards as adopted by the EU.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 4 of 35

COMMERCIAL EXECUTION
SALES DEVELOPMENT ACROSS THERAPEUTIC AREAS
Sales grew by 25% measured in Danish kroner and by 26% at CER in 2024, driven by Diabetes care sales growth of 20% (CER) and Obesity care sales growth of 57% (CER). Rare disease sales increased by 9% (CER). Sales growth has resulted in periodic supply constraints and related drug shortage notifications across a number of products and geographies. Sales growth in the US was positively impacted by gross-to-net sales adjustments.

Sales split per therapy | Sales 2024 DKK million | Sales 2023 DKK million |  | Growth as reported | Growth at CER | Share of growth at CER
Diabetes and Obesity care segment |  |  |  |  |  |
Injectable GLP-1 | 125,824 |  | 104,382 |  |  | 21 | % | 21 | % | 37 | %
| - Ozempic® | 120,342 |  | 95,718 |  |  | 26 | % | 26 | % | 42 | %
| - Victoza® | 5,482 |  | 8,664 |  |  | (37 | %) | (36 | %) | (5 | %)
Rybelsus® | 23,301 |  | 18,750 |  |  | 24 | % | 26 | % | 8 | %
Total GLP-1 | 149,125 |  | 123,132 |  |  | 21 | % | 22 | % | 45 | %
Long-acting insulin 1 | 19,095 |  | 14,905 |  |  | 28 | % | 30 | % | 7 | %
Premix insulin 2 | 10,789 |  | 9,574 |  |  | 13 | % | 14 | % | 2 | %
Fast-acting insulin 3 | 18,522 |  | 15,949 |  |  | 16 | % | 16 | % | 4 | %
Human insulin | 6,967 |  | 7,594 |  |  | (8 | %) | (6 | %) | (1 | %)
Total insulin | 55,373 |  | 48,022 |  |  | 15 | % | 17 | % | 12 | %
Other Diabetes care 4 | 2,120 |  | 2,312 |  |  | (8 | %) | (7 | %) | 0 | %
Total Diabetes care | 206,618 |  | 173,466 |  |  | 19 | % | 20 | % | 57 | %
Wegovy® | 58,206 |  | 31,343 |  |  | 86 | % | 86 | % | 45 | %
Saxenda® | 6,940 |  | 10,289 |  |  | (33 | %) | (32 | %) | (5 | %)
Total Obesity care | 65,146 |  | 41,632 |  |  | 56 | % | 57 | % | 40 | %
Diabetes and Obesity care total | 271,764 |  | 215,098 |  |  | 26 | % | 27 | % | 97 | %
Rare disease segment |  |  |  |  |  |
Rare blood disorders 5 | 12,138 |  | 11,776 |  |  | 3 | % | 3 | % | 1 | %
Rare endocrine disorders 6 | 4,993 |  | 3,836 |  |  | 30 | % | 31 | % | 2 | %
Other Rare disease 7 | 1,508 |  | 1,551 |  |  | (3 | %) | (2 | %) | 0 | %
Rare disease total | 18,639 |  | 17,163 |  |  | 9 | % | 9 | % | 3 | %
Total sales | 290,403 |  | 232,261 |  |  | 25 | % | 26 | % | 100 | %
1) Comprises Tresiba®, Xultophy®, Levemir® and Awiqli® |  |  |  |
2) Comprises Ryzodeg® and NovoMix®. |  |  |  |
3) Comprises Fiasp® and NovoRapid®. |  |  |  |
4) Primarily NovoNorm®, needles and GlucaGen® HypoKit®. |  |  |  |
5) Comprises NovoSeven®, NovoEight®, Esperoct®, Refixia®, NovoThirteen® and Alhemo®. |  |
6) Primarily Norditropin® and Sogroya®. |  |  |  |
7) Primarily Vagifem® and Activelle®.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 5 of 35

DIABETES AND OBESITY CARE
Diabetes care, sales and market share development
Sales in Diabetes care increased by 19% measured in Danish kroner and by 20% at CER to DKK 206,618 million driven by growth of GLP-1-based products and insulins. Novo Nordisk's global diabetes value market share remains unchanged over the last 12 months at 33.7% in line with the strategic aspiration of strengthening the Diabetes care leadership, aiming at reaching a global value market share of more than one-third in 2025. The market share was driven by market share gains in North America Operations, offset by a market share decline in International Operations.
In the following sections, unless otherwise noted, market data are based on moving annual total (MAT) from November 2023 and November 2024 provided by the independent data provider IQVIA. EMEA covers Europe, the Middle East and Africa; Region China covers mainland China, Hong Kong and Taiwan; Rest of World covers all other countries except for North America.

Diabetes care, development per geographical area | Novo Nordisk’s share of the total diabetes market (value, MAT) | Diabetes care, sales development
|  | November | November | Sales 2024 DKK million | Growth at CER
|  | 2024 | 2023
Global | 33.7 | % | 33.7 | % | 206,618 |  | 20 | %
North America Operations | 35.4 | % | 35.1 | % | 120,812 |  | 26 | %
| - The US | 34.8 | % | 34.7 | % | 112,386 |  | 28 | %
International Operations | 27.7 | % | 28.2 | % | 85,806 |  | 12 | %
| - EMEA * | 28.7 | % | 30.4 | % | 44,266 |  | 12 | %
| - Region China ** | 32.8 | % | 32.3 | % | 17,790 |  | 13 | %
| - Rest of World *** | 23.9 | % | 23.0 | % | 23,750 |  | 11 | %

Source: IQVIA, November 2024 data. *Data for EMEA available for European markets and seven markets outside Europe representing approximately 90% of Novo Nordisk Diabetes care sales in the area. **Data for mainland China, excluding Hong Kong and Taiwan. *** Data for Rest of World available for seven markets representing approximately 70% of total Novo Nordisk’s Diabetes care sales in the area.
GLP-1-based therapies for type 2 diabetes
Sales of GLP-1-based products for type 2 diabetes (Rybelsus®, Ozempic® and Victoza®) increased by 21% measured in Danish kroner and by 22% at CER to DKK 149,125 million. The estimated global GLP-1 share of total diabetes prescriptions has increased to 6.7% compared with 6.0% 12 months ago. Novo Nordisk is the global market leader in the GLP-1 segment with a 55.1% value market shar e.

GLP-1 diabetes, development per geographical area | Novo Nordisk's share of the diabetes GLP-1 market (value, MAT) | GLP-1 diabetes, sales development
|  | November | November | Sales 2024 DKK million | Growth at CER
|  | 2024 | 2023
Global | 55.1 | % | 54.8 | % | 149,125 |  | 22 | %
North America Operations | 54.1 | % | 53.1 | % | 104,153 |  | 23 | %
| - The US | 53.2 | % | 52.1 | % | 96,695 |  | 24 | %
International Operations | 63.6 | % | 69.3 | % | 44,972 |  | 18 | %
| - EMEA * | 55.8 | % | 63.0 | % | 24,559 |  | 18 | %
| - Region China ** | 79.6 | % | 76.6 | % | 7,248 |  | 19 | %
| - Rest of World *** | 81.3 | % | 83.8 | % | 13,165 |  | 18 | %

Source: IQVIA, November 2024 data. *Data for EMEA available for European markets and seven markets outside Europe representing approximately 90% of Novo Nordisk GLP-1 sales in the area. **Data for mainland China, excluding Hong Kong and Taiwan. ***Data for Rest of World available for seven markets representing approximately 70% of total Novo Nordisk Diabetes care sales in the area. Note: the estimated GLP-1 share of prescriptions is based on volume packs from IQVIA. Volume packs are converted into full-year patients/prescriptions based on WHO assumptions for average daily doses or if not available, Novo Nordisk assumptions.
Ozempic® sales increased by 26% in both Danish kroner and at CER to DKK 120,342 million. Sales growth was driven by both North America Operations and International Operations. Sales growth has resulted in periodic supply constraints and related drug shortage notifications across geographies.
Rybelsus® sales increased by 24% measured in Danish kroner and by 26% at CER to DKK 23,301 million. Sales growth was driven by EMEA and Rest of World.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 6 of 35

Victoza® sales decreased by 37% measured in Danish kroner and by 36% at CER to DKK 5,482 million. The decline was driven by the GLP-1 diabetes market moving towards once-weekly treatments in both North America Operations and International Operations.
North America Operations
Sales of GLP-1 Diabetes care products in North America Operations increased by 23% in both Danish kroner and at CER. Novo Nordisk is the market leader with a 54.1% v alue market share. The estimated GLP-1 share of total diabetes prescriptions has increased to 17.7% compared with 15.5% 12 m onths ago.
Sales of GLP-1 Diabetes care products in the US increased by 24% at CER. The sales increase was mainly driven by continued uptake of Ozempic®.
Sales grow th in the US was mainly driven by a prescription volume growth of the GLP-1 class above 15% in the fourth quarter of 2024 compared with the fourth quarter of 2023. Novo Nordisk is the market leader, with 52.2% measured by total monthly prescriptions and 47.8% measured by new-to-brand prescriptions.
International Operations
S ales of GLP-1 Diabetes care products in International Operations increased by 16% measured in Danish kroner and by 18% at CER, driven by all Regions. The estimated GLP-1 share of total diabetes prescriptions has increased to 4.2% compared with 3.8% 12 months ago. Novo Nordisk is the market leader with a value market share of 63.6% compared with 69.3% 12 months ago. The sales growth has resulted in periodic supply constraints and related drug shortage notifications across a number of products and geogra phies.
EMEA
Sales of GLP-1 Diabetes care products in EMEA increased by 18% in both Danish kroner and at CER. The sales growth reflects the uptake of Rybelsus® and Ozempic®, partially offset by lower sales of Victoza®. The estimated GLP-1 share of total diabetes prescriptions has increased to 5.7% compared with 5.2% 12 months ago. Novo Nordisk is the market leader in EMEA with a value market share of 55.8%.
Region China
Sales of GLP-1 Diabetes care products in Region China increased by 17% measured in Danish kroner and by 19% at CER. The sales growth mainly reflects the uptake of Ozempic®, p artially countered by lower sales of Victoza®. GLP-1 sales growth was negatively impacted by periodic supply constraints. The GLP-1 sh are of total diabetes prescriptions has decreased to 3.1% compared with 3.3% 12 months ago. Novo Nordisk is the market leader in Region China with a value market share of 79.6%.
Rest of World
Sales of GLP-1 Diabetes care products in Rest of World increased by 13% measured in Danish kroner and by 18% at CER. The sales growth reflects increased sa les of Rybelsus®, partially offset by lower sales of Victoza®. The estimated GLP-1 share of total diabetes prescriptions has increased to 2.7% compared with 2.3% 12 months ago. Novo Nordisk is the market leader with a value market share of 81.3%.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 7 of 35

Insulin
Sales of insulin increased by 15% measured in Danish kroner and by 17% at CER to DKK 55,373 million.

Insulin, development per geographical area | Novo Nordisk’s share of the total insulin market (volume, MAT) | Insulin, sales development
|  | November | November | Sales 2024 DKK million | Growth at CER
|  | 2024 | 2023
Global | 44.0 | % | 45.3 | % | 55,373 |  | 17 | %
North America Operations | 32.8 | % | 36.7 | % | 16,395 |  | 52 | %
| - The US | 32.5 | % | 36.4 | % | 15,478 |  | 57 | %
International Operations | 47.6 | % | 48.4 | % | 38,978 |  | 6 | %
| - EMEA * | 47.3 | % | 47.6 | % | 19,019 |  | 5 | %
| - Region China ** | 41.5 | % | 40.9 | % | 9,760 |  | 12 | %
| - Rest of World *** | 55.4 | % | 57.7 | % | 10,199 |  | 3 | %

Source: IQVIA, November 2024 data. *Data for EMEA available for European markets and seven markets outside Europe representing approximately 90% of Novo Nordisk insulin sales in the area. **Data for mainland China, excluding Hong Kong and Taiwan. ***Data for Rest of World available for seven markets representing approximately 70% of total Novo Nordisk Diabetes care sales in the area.
North America Operations
Sales of insulin in North America Operations increased by 52% in both Danish kroner and at CER. The sales increase in the US was driven by by gross-to-net sales adjustments and channel and payer mix, partially countered by a decline in volume. Novo Nordisk has a volume market share of 32.5% of the total US insulin market.
International Operations
Sales of insulin in International Operations increased by 5% measured in Danish kroner and by 6% at CER. The sales increase at CER was driven by Region China and EMEA. Novo Nordisk has a volume market share of 47.6% o f the total insulin market in International Operations.
EMEA
Sales of insulin in EMEA increased by 4% measured in Danish kroner and by 5% at CER. The sales increase at CER was d riven by long-acting insulin and fast-acting insulin, partially countered by human insulin. Novo Nordisk has a volume market share of 47.3% of the total insulin market.
Region China
Sales of insulin in Region China increased by 10% measured in Danish kroner and by 12% at CER. The sales increase at CER was mainly driven by long-acting insulin and premix insulin, partially countered by human insulin. Novo Nordisk has a volume market share of 41.5% of the total insulin market.
Rest of World
Sales of insulin in Rest of World increased by 1% measured in Danish kroner and by 3% at CER. The sales increase at CER was mainly driven by premix insulin, partially countered by human insulin. Novo Nordisk has a volume market share of 55.4% of the total insulin market.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 8 of 35

Obesity care, sales development
Sales of Obesity care products, Wegovy® and Saxenda®, increased by 56% measured in Danish kroner and by 57% at CER to DKK 65,146 million. Sales growth was driven by bot h North America Operations and International Operations. The volume growth of the global branded obesity market was 119%. Novo Nordisk is the global market leader with a volume market share of 70.4%.

Obesity care, development per geographical area | Global branded obesity market growth (Volume, MAT) | Obesity care, sales development
|  | November |  | Sales 2024 DKK million | Growth at CER
|  | 2024 |
Global | 119 | % |  | 65,146 |  | 57 | %
North America Operations | 149 | % |  | 48,158 |  | 45 | %
| - The US | 152 | % |  | 46,547 |  | 42 | %
International Operations | 73 | % |  | 16,988 |  | 107 | %
| - EMEA * | 72 | % |  | 10,433 |  | 83 | %
| - Region China** | N/A |  | 298 |  | 108 | %
| - Rest of World*** | 76 | % |  | 6,257 |  | 162 | %

Source: IQVIA, November 2024 data. *Data for EMEA available for European markets and seven markets outside Europe representing approximately 90% of Novo Nordisk obesity care sales in the area. **Data for mainland China, excluding Hong Kong and Taiwan. ***Data for Rest of World available for seven markets representing approximately 70% of total Novo Nordisk Diabetes care sales in the area.
Wegovy® sales increased by 86% in both Danish kroner and at CER to DKK 58,206 million. Sales of Saxenda® decreased by 33% measured in Danish kroner and by 32% at CER to DKK 6,940 million as the obesity care market is moving towards once-weekly treatments.
North America Operations
Sales of Obesity care products in North America Operations increased by 45% in both Danish kroner and at CER to DKK 48,158 million. Sales of Wegovy® increased by 59% in both Danish kroner and at CER to DKK 46,781 million, driven by increased volumes, partially countered by lower realised prices. Broad commercial formulary access has been achieved for Wegovy®. In the US, Wegovy® has around 200,000 weekly prescriptions, compared to around 100,000 weekly prescriptions in January 2024, and aroun d 20,000 weekly n ew-to-brand prescriptions. Sales of Saxenda® decreased by 65% measured in Danish kroner and by 64% at CER to DKK 1,377 million. The volume growth of the branded obesity market in the US was 152%.
International Operations
Sales of Obesity care p roducts in International Operations increased by 104% measured in Danish kroner and by 107% at CER to DKK 16,988 million, mainly d riven by increased sales in EMEA and Rest of World. Sales of Saxenda® in In ternational Operations decreased by 13% measured in Danish kroner and by 12% at CER to DKK 5,563 million, and sales of Wegovy® reached DKK 11,425 million. Wegovy® has now been launched in more than 15 countries i n International Operations. The volume growth of the branded obesity market in International Operations was 73%.
EMEA
Sales of Obesity care products in EMEA increased by 83% in both Danish kroner and at CER to DKK 10,433 million driven by Wegovy®, partially countered by declining Saxenda® sales. The volume growth of the branded obesity market in EMEA was 72%.
Region China
Sales of Obesity care products in Region China increased by 104% measured in Danish kroner and by 108% at CER to DKK 298 million. Wegovy® was launched in China in November 2024.
Rest of World
Sales of Obesity care products in Rest of World increased by 153% measured in Danish kroner and by 162% at CER to DKK 6,257 million, driven by uptake of Wegovy®. The volume of the branded obesity market in Rest of World increased by 76%.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 9 of 35

Rare disease, sales development
Rare disease sales increased by 9% in both Danish kroner and at CER to DKK 18,639 million. Sal es of rare endocrine disorder products increased by 30% measured in Danish kroner and by 31% at CER to DKK 4,993 million. Novo Nordisk is working on gradually re-establishing supply of rare endocrine disorder products following a reduction of manufacturing output. Sogroya® has been launched in six countries, and the initial feedback from patients and physicians is encouraging. Sales of rare blood disorder products increased by 3% in both Danish kroner and at CER to DKK 12,138 million mainly driven by increased haemophilia B sales.

Rare disease, development per geographical area | Rare disease, sales development
|  | Sales 2024 DKK million | Growth at CER
Global | 18,639 |  | 9 | %
North America Operations | 9,202 |  | 20 | %
| - The US | 8,469 |  | 20 | %
International Operations | 9,437 |  | 0 | %
| - EMEA | 5,703 |  | 4 | %
| - Region China | 413 |  | (30 | %)
| - Rest of World | 3,321 |  | 0 | %

North America Operations
Rare disease sales in North America Operations increased by 20% in both Danish kroner and at CER. The sales increase was driven by rare endocrine disorder products increasing by 65% in both Danish kroner and at CER, driven by the launch of Sogroya® and increased Norditropin® supply as well as impact from gross-to-net sales adjustments in the US. Sales of rare blood disorder products increased by 7% in both Danish kroner and at CER, mainly driven by increased haemophilia B sales and NovoSeven®.
International Operations
Rare disease sales in International Operations remained unchanged both in Danish kroner and at CER. The sales were driven by both rare blood disorder and rare endocrine disorder products. Sales of rare blood disorder products remained unchanged in Danish kroner and increased by 1% at CER, driven by increased sales of haemophilia B products, partially countered by lower sales of NovoSeven®. Rare endocrine disorder products decreased by 1% measured in Danish kroner and increased by 2% at CER. Sogroya® has now been launched in five countries in International Operations with encouraging initial feedback.
EMEA
Rare disease sales increased by 4% in both Danish kroner and at CER. Sales of rare blood disorder products decreased by 2% in both Danish kroner and CER, driven by lower NovoSeven® and haemophilia A sales, partially countered by increased haemophilia B sales. The increased sales of haemophilia B sales reflect the continued uptake of extended half-life products. Rare endocrine disorder products increased by 48% in both Danish kroner and at CER.
Region China
Rare disease sales decreased by 30% in both Danish kroner and CER, mainly driven by decreased sales of rare endocrine products.
Rest of World
Rare disease sales decreased by 2%, measured in Danish kroner, and remained unchanged at CER. Sales of rare endocrine disorder products decreased by 16% measured in Danish kroner and by 11% at CER, reflecting a reduction in manufacturing output. Sales of rare blood disorder products increased by 6% measured in Danish kroner and by 7% at CER, driven by higher sales of NovoSeven®.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 10 of 35

FINANCIALS
GEOGRAPHIC SALES DEVELOPMENT
Sales increased by 25% measured in Danish kroner and by 26% at CER to DKK 290,403 million in 2024. Sales growth has resulted in periodic supply constraints and related drug shortage notifications across a number of products and geographies. In North America Operations, sales increased by 30% in both Danish kroner and at CER. Sales in International Operations increased by 17% measured in Danish kroner and by 19% at CER.

Sales split per geographical area | Sales 2024 DKK million | Growth as reported | Growth at CER | Share of growth at CER
North America Operations | 178,172 |  | 30 | % | 30 | % | 70 | %
| - The US | 167,402 |  | 31 | % | 31 | % | 67 | %
International Operations | 112,231 |  | 17 | % | 19 | % | 30 | %
| - EMEA | 60,402 |  | 19 | % | 19 | % | 16 | %
| - Region China | 18,501 |  | 11 | % | 13 | % | 3 | %
| - Rest of World | 33,328 |  | 19 | % | 23 | % | 11 | %
Total sales | 290,403 |  | 25 | % | 26 | % | 100 | %

North America Operations
Sales in North America Operations increased by 30% in both Danish kroner and at CER, positively impacted by gross-to-net sales adjustments. The sales increase reflects GLP-1 diabetes sales growing by 23% at CER, Obesity care sales growing by 45% at CER and insulin sales increasing by 52% at CER. Rare disease sales increased by 20% at CER.
International Operations
Sales in International Operations increased by 17% measured in Danish kroner and by 19% at CER. Sales growth was driven by Obesity care sales growing by 107% at CER and GLP-1 diabetes sales growing by 18% at CER. GLP-1 diabetes sales growth was negatively impacted by periodic supply constraints. I nsulin sales are growing by 6% at CER, while Rare disease sales are unchanged at CER.
EMEA
Sales in EMEA increased by 19% in both Danish kroner and at CER. Sales growth was driven by Obesity care growing by 83% at CER. Diabetes care sales increased by 12% at CER, driven by GLP-1 diabetes sales growing by 18% at CER and insulin sales growing by 5% at CER. Rare disease sales increased by 4% at CER.
Region China
Sales in Region China increased by 11% measured in Danish kroner and by 13% at CER. The sales increase at CER was driven by GLP-1 diabetes sales growing by 19% at CER and insulin sales increasing by 12% at CE R. Other diabetes care sales decreased by 11% at CER. Rare disease sales decreased by 30% at CER.
Rest of World
Sales in Rest of World increased by 19% measured in Danish kroner and by 23% at CER. Sales growth was driven by Obesity care sales increasing by 162% at CER and Diabetes care growing by 11% at CER, reflecting increased GLP-1 diabetes sales growing 18% at CER. Rare diseases sales are unchanged at CER.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 11 of 35

DEVELOPMENT IN COSTS AND OPERATING PROFIT
The cost of goods sold increased by 24% measured in Danish kroner and by 25% at CER to DKK 44,522 million, resulting in a gross margin of 84.7%, measured in Danish kroner, compared with 84.6% in 2023. The increase in gross margin mainly reflects a positive product mix driven by increased sales of GLP-1-based treatments and a positive price impact due to gross-to-net sales adjustments in the US. This is partially countered by costs related to ongoing capacity expansions.
Sales and distribution costs increased by 9% measured in Danish kroner and by 10% at CER to DKK 62,101 million. The increase in costs is driven by both North America Operations and International Operations. In North America Operations, t he cost increase is mainly driven by promotional activities related to Wegovy®. In International Operations, the increase is mainly related to Obesity care market development activities and Wegovy® launch activities as well as promotional activities for GLP-1 diabetes products. The increase in sales and distribution costs is negatively impacted by adjustments to legal provisions in 2023. Sales and distribution costs amounted to 21.4% as a percentage of sales.
Research and development costs increased by 48% in both Danish kroner and at CER to DKK 48,062 million compared to 2023, mainly reflecting increased late-stage clinical trial activity, increased early research activities as well as impairment losses related to intangible assets. Research and development costs amounted to 16.6% as a percentage of sales.
Administration costs increased by 9% in both Danish kroner and at CER to DKK 5,276 million. Administration costs amounted to 1.8% as a percentage of sales.
Other operating income and expenses (net) showed a loss of DKK 2,103 million compared to an income of DKK 119 million in 2023. The loss is mainly reflecting impairments related to a partnership agreement of a company previously acquired by Novo Nordisk and transaction costs related to the Catalent transaction.
Operating profit increased by 25% measured in Danish kroner and by 26% at CER to DKK 128,339 million, reflecting the sales growth and impairments related to intangible assets. EBITDA increased by 32% measured in Danish kroner and by 33% at CER.
Financial items (net) showed a net loss of DKK 1,148 million, compared with a net gain of DKK 2,100 million in 2023. This primarily reflects losses on non-hedged currencies.
In line with Novo Nordisk’s treasury policy, the most significant foreign exchange risks for Novo Nordisk have been hedged, primarily through foreign exchange forward contracts. The foreign exchange result was a net loss of DK K 1,023 million compared with a net gain of DKK 1,652 million in 2023.
As per the end of December 2024, a negative market value of financial contracts of approximately DKK 5.8 billion has been deferred for recognition in 2025.
The effective tax rate was 20.6% in 2024, compared with an effective tax rate of 20.1% in 2023.
Net profit increased by 21% to DKK 100,988 million and diluted earnings per share increased by 22% to DKK 22.63. Net profit and diluted earnings per share are impacted by impairments related to intangible assets.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 12 of 35

KEY DEVELOPMENTS IN THE FOURTH QUARTER OF 2024
Sales in the fourth quarter of 2024 increased by 30% in both Danish kroner and at CER co mpared to 2023. Sales growth is positively impacted by gross-to-net adjustments in the US. Operating profit increased by 37% in both Danish kroner and at CER. Sales growth has resulted in periodic supply constraints and related drug shortage notifications across a number of products and geographies. Please refer to appendix 1 for an overview of the quarterly numbers in DKK and to appendix 6 for additional details on sales in the fourth quarter of 2024.

Sales split per geographical area | Sales Q4 2024 DKK million | Growth as reported | Growth at CER | Share of growth at CER
North America Operations | 55,364 |  | 30 | % | 29 | % | 63 | %
| - The US | 52,372 |  | 31 | % | 30 | % | 60 | %
International Operations | 30,319 |  | 30 | % | 32 | % | 37 | %
| - EMEA | 16,759 |  | 32 | % | 32 | % | 20 | %
| - Region China | 4,324 |  | 27 | % | 24 | % | 4 | %
| - Rest of World | 9,236 |  | 30 | % | 36 | % | 13 | %
Total sales | 85,683 |  | 30 | % | 30 | % | 100 | %

The increased global sales of 30% at CER were driven by increased sales across the portfolio. GLP-1 diabetes sales increased by 12% at CER and Obesity care sales increased by 91% at CER. Insulin sales increased by 36% at CER and Rare disease sales increased by 25% at CER.
North America Operations
Sales in North America Operations increased by 30% measured in Danish kroner and by 29% at CER. Sales growth was driven by GLP-1 diabetes sales growing by 7% at CER. Ozempic® sales growth was negatively impacted by one-off comparator effects in fourth quarter of 2023. Obesity care sales increased by 79% at CER. Insulin sales increased by 112% at CER, positively impacted by gross-to-net adjustments, partially countered by lower realised volumes. Rare disease sales increased by 18% at CER, mainly driven by volume growth for rare endocrine disorder products and gross-to-net sales adjustments.
International Operations
Sales in International Operations increased by 30% measured in Danish kroner and by 32% at CER. Sales growth was driven by all Regions.
Sales growth was driven by Diabetes and Obesity care growing by 32% at CER, driven by Obesity care increasing by 139% at CER following uptake of Wegovy®. GLP-1 diabetes sales grew by 26% at CER, and insulin sales increased by 13% at CER. Rare disease sales increased by 35% at CER.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 13 of 35

PROFIT AND LOSS | Q4 2024 | Q4 2023 |  | % change Q4 2024 to Q4 2023 |  | % change Q4 2024 to Q4 2023 at CER
Net sales | 85,683 | 65,863 |  | 30 | % |  | 30 | %
Gross profit | 72,659 | 55,849 |  | 30 | % |  | 30 | %
Gross margin | 84.8% | 84.8% |  |  |  |
Sales and distribution costs | (18,701) | (17,170) |  | 9 | % |  | 9 | %
Percentage of sales | 21.8% | 26.1% |  |  |  |
Research and development costs | (13,802) | (10,460) |  | 32 | % |  | 31 | %
Percentage of sales | 16.1% | 15.9% |  |  |  |
Administrative costs | (1,580) | (1,456) |  | 9 | % |  | 9 | %
Percentage of sales | 1.8% | 2.2% |  |  |  |
Other operating income and expenses | (1,839) | 3 |  | N/A |  | N/A
Operating profit (EBIT) | 36,737 | 26,766 |  | 37 | % |  | 37 | %
Operating margin | 42.9% | 40.6% |  |  |  |
Financial items (net) | (1,180) | 854 |  | N/A |  | N/A
Profit before income taxes | 35,557 | 27,620 |  | 29 | % |  | N/A
Income taxes | (7,327) | (5,657) |  | 30 | % |  | N/A
Effective tax rate | 20.6% | 20.5% |  |  |  |
Net profit | 28,230 | 21,963 |  | 29 | % |  | N/A
Net profit margin | 32.9% | 33.3% |  |  |  |

Costs and operating profit
The gross margin was realised at 84.8% in the fourth quarter of 2024 compared with 84.8% in 2023. The gross margin is unchanged due to a positive product mix driven by increased sales of GLP-1-based treatments and a positive price impact due to gross-to-net sales adjustments in the US. This is partially countered by costs related to ongoing capacity expansions as well as costs related to impairments of assets, as well as Catalent amortisations
Sales and distribution costs increased by 9% in both Danish kroner and at CER compared with 2023, impacted by adjustments to legal provisions in 2023. T he increase in costs is driven by both North America Operations and International Operations. In North America Operations, t he cost increase is mainly driven by promotional activities related to Wegovy®. In International Operations, the increase is mainly related to Obesity care market development activities and Wegovy® launch activities. Sales and distribution costs amounted to 21.8% as a percentage of sales.
Research and development costs increased by 32% measured in Danish kroner and by 31% at CER compared with 2023. This is driven by both increased late-stage clinical trial and research activities mainly related to Diabetes and Obesity Care as well as impairments related to intangible assets. Research and development costs amounted to 16.1% as a percentage of sales.
Administrative costs increased by 9% in both Danish kroner and at CER compared with the same period in 2023. Administration costs amounted to 1.8% as a percentage of sales.
Other operating income and expenses showed a loss of DKK 1,839 million in the fourth quarter of 2024. The loss is mainly reflecting impairments related to a partnership agreement of a company previously acquired by Novo Nordisk and transaction costs related to the Catalent transaction.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 14 of 35

Operating profit increased by 37% in both Danish kroner and at CER compared with the fourth quarter of 2023. EBITDA increased by both 41%, measured in Danish kroner and by 41% at CER.
Financial items (net) showed a net loss of DKK 1,180 million compared with a net gain of DKK 854 million in the fourth quarter of 2023, mainly reflecting losses on hedged currencies, primarily the US dollar.
The effective tax rate is 20.6% in the fourth quarter of 2024 compared with an effective tax rate of 20.5% in the fourth quarter of 2023.
Net profit increased by 29% to DKK 28,230 million and diluted earnings per share increased by 29% to DKK 6.34.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 15 of 35

CASH FLOW AND CAPITAL ALLOCATION
FREE CASH FLOW IN 2024 AND CAPITAL EXPENDITURE
Free cash flow in 2024 was realised at DKK (14.7) billion compared to DKK 68.3 billion in 2023. The lower free cash flow in 2024 is mainly impacted by the USD 11.7 billion acquisition price related to the three Catalent manufacturing sites. Free cash flow is also impacted by increasing capital expenditure, partially countered by net cash generated from operating activities.
Capital expenditure for property, plant and equipment was DKK 47.2 billion compared with DKK 25.8 billion in 2023, primarily reflecting investments in additional capacity for active pharmaceutical ingredient (API) production and fill-finish capacity for both current and future injectable and oral products. Capital expenditure related to intangible assets was DKK 4.1 billion in 2024 compared with DKK 13.1 billion in 2023, reflecting business development activities.
Income under the 340B Program has been partially recognised.
Novo Nordisk has acquired three fill-finish sites from Novo Holdings A/S in connection with the Catalent, Inc. transaction
In February 2024, Novo Nordisk announced an agreement to acquire three fill-finish sites from Novo Holdings A/S (Novo Holdings) in connection with a transaction where Novo Holdings has agreed to acquire Catalent, Inc. (Catalent), a global contract development and manufacturing organisation. As announced, the acquisition was completed on 18 December 2024. For further information, please see the company announcement here: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915081#:~:text=The%20acquisition%20of%20Catalent%20by,from%20Novo%20Holdings%20A%2FS (The contents of the company's website do not form a part of this Form 6-K).
EQUITY AND CAPITAL ALLOCATION
Total equity was DKK 143,486 million at the end of 2024, equivalent to 30.8% of total assets, compared with 33.9% at the end of 2023. Please refer to appendix 5 for further elaboration of changes in equity. Novo Nordisk returned DKK 64.3 billion to shareholders via DKK 20.2 billion share buybacks and DKK 44.1 billion dividend during 2024.
Proposed final dividend of DKK 7.90 for each Novo Nordisk A and B share of DKK 0.10
At the Annual General Meeting on 27 March 2025, the Board of Directors will propose a final dividend of DKK 7.90 for each Novo Nordisk A and B share of DKK 0.10. The total dividend for 2024 of DKK 11.40 for each Novo Nordisk A and B share of DKK 0.10 includes both the interim dividend of DKK 3.50 for each Novo Nordisk A and B share of DKK 0.10, which was paid in August 2024, and the proposed final dividend of DKK 7.90 for each Novo Nordisk A and B share of DKK 0.10 to be paid 1 April 2025. Hence, the total dividend per share is expected to increase by 21.3% compared with the 2023 dividend of DKK 9.40 for each Novo Nordisk A and B share of DKK 0.10. The total dividend for 2024 corresponds to a payout ratio of 50.2% which is similar to the payout ratio for Novo Nordisk's peer group of comparable pharmaceutical companies in 2023. No dividend will be paid on the company's holding of own B shares.
Share repurchase programme
As of 3 February 2025, Novo Nordisk has repurchase d 24,802,593 B shares of DKK 0.10 for an amount of DKK 20 billion as part of the overall share repurchase programme of up to DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The purpose of the programme was to reduce the company's share capital and to meet obligations arising from share-based incentive programmes. The programme was concluded on 3 February 2025. As of 3 February 2025, Novo Nordisk and its wholly-owned affiliates owned 25,947,151 of its own B shares, corresponding to 0.6% of the total share capital.
Novo Nordisk’s capital allocation priorities focus on attractive internal growth investments, including the significant supply chain expansion and a dividend pay-out ratio around 50% of net profit. Following the further step-up in CAPEX investments in 2025, Novo Nordisk is not initiating a new share buyback programme. An authorisation to the Board of Directors to buy back shares will, however, in line with previous years, be proposed at the Annual General Meeting should the initiation of a share buyback programme later be deemed relevant. As the Board of Directors prioritises to meet obligations arising from

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 16 of 35

current and future share-based incentive programmes, a reduction in the B share capital will not be proposed at the Annual General Meeting in March 2025.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 17 of 35

OUTLOOK
The current expectations for 2025 are summarised in the table below:

r |  |  |
Expectations are as reported, if not otherwise stated |  | Expectations 5 February 2025 |
Sales growth |  |  |
at CER |  | 16% to 24% |
as reported |  | Around 3 percentage points higher than at CER |
Operating profit growth |  |  |
at CER |  | 19% and 27% |
as reported |  | Around 5 percentage points higher than at CER |
Financial items (net) |  | Loss of around 9 bDKK |
Effective tax rate |  | 21% to 23% |
Capital expenditure (PP&E) |  | Around 65 bDKK |
Depreciation, amortisation and impairment losses |  | Around DKK 17 billion |
Free cash flow (excluding impact from business development) |  | Between 75 and 85 bDKK |

Sales growth is expected to be 16% to 24% at CER. Given the current exchange rates versus the Danish krone, sales growth reported in DKK is expected to be 3 percentage points higher than at CER.
The guidance reflects expectations for sales growth in both North America Operations and International Operations, mainly driven by volume growth of GLP-1-based treatments for Obesity and Diabetes care. Intensifying competition and continued pricing pressure within Diabetes and Obesity care is included in the guidance.
Following higher-than-expected volume growth in recent years, including GLP-1-based products such as Ozempic® and Wegovy®, combined with the expectation of continued volume growth and capacity limitations at some manufacturing sites, the outlook also reflects expected continued periodic supply constraints and related drug shortage notifications across a number of products and geographies. Novo Nordisk is investing in internal and external capacity to increase supply both short and long-term.
Operating profit growth is expected to be 19% to 27% at CER. Given the current exchange rates versus the Danish krone, growth reported in DKK is expected to be 5 percentage points higher than at CER. The expectation for operating profit growth primarily reflects the sales growth outlook and continued investments in future and current growth drivers within Research, Development, Commercial and Manufacturing. Within R&D, investments are related to the continued expansion and progression of the early and late-stage pipeline. Commercial investments are mainly related to Obesity care market development and activities as well as investments within GLP-1 diabetes care. Within Manufacturing, investments are mainly related to ongoing scaling of capacity efforts, and a negative mid-single-digit operating profit growth impact related to the acquisition of the three Catalent manufacturing sites is also included in the guidance.
Novo Nordisk expects financial items (net) for 2025 to amount to a loss of around DKK 9 billion. This is driven by expected losses on hedged currencies, primarily the US dollar due to the increased USD/DKK rate, and increased interest expenses related to funding of the Catalent transaction, as the acquisition is mainly debt-financed.
The effective tax rate for 2025 is expected to be in the range of 2 1-23%. The increase compared to 2024 is mainly driven by country and therapy sales mix.
Capital expenditure is expected to be around 65 billion DKK in 2025, reflecting expansion of the global supply chain. The investments will create additional capacity across the supply chain, including manufacturing of active pharmaceutical ingredients (API), additional aseptic production and finished production processes as well as packaging capacity. In the coming years, the capital expenditure to sales ratio is still expected to be low double-digit.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 18 of 35

Depreciation, amortisation and impairment losses are expected to be around DKK 17 billion, and include depreciations and amortisations related to the Catalent transaction.
The free cash flow is expected to be DKK 75-85 billion reflecting the sales growth, a favourable impact from rebates in the US, countered by increased investments in capital expenditure.
All of the above expectations are based on assumptions that the global or regional macroeconomic and political environment will not significantly change business conditions for Novo Nordisk during 2025, including energy and supply chain disruptions, the potential implications from major healthcare reforms and legislative changes, taxation changes, including changes in tariffs and duties, as well as outcome of legal cases including litigations related to the 340B Drug Pricing Program in the US, and that the currency exchange rates, especially the US dollar, will remain at the current level versus the Danish krone. The guidance is also based on assumptions in relation to the estimation of gross-to-net developments in the US gross sales. Finally, the guidance does not include the financial implications of any new significant business development transactions and significant impairments of intangible assets during 2025.

FX (average rates) | Q4 2024 | Q4 2023 | % change |  |  |  | 2024 | 2023 | % change | Spot rate 30 January 2025
USD | 697 |  | 694 |  | 0 | % |  |  |  | 689 |  | 689 |  | 0 | % | 717 |
CNY | 97 |  | 96 |  | 1 | % |  |  |  | 96 |  | 97 |  | (1 | %) | 99 |
JPY | 4.59 |  | 4.69 |  | (2 | %) |  |  |  | 4.56 |  | 4.91 |  | (7 | %) | 4.65 |
CAD | 500 |  | 509 |  | (2 | %) |  |  |  | 503 |  | 511 |  | (2 | %) | 498 |
BRL | 120 |  | 140 |  | (14 | %) |  |  |  | 129 |  | 138 |  | (7 | %) | 121 |

Novo Nordisk has hedged expected net cash flows in a number of invoicing currencies, and, all other things being equal, movements in key invoicing currencies will impact Novo Nordisk’s operating profit as outlined in the table below.

Key invoicing currencies | Impact on Novo Nordisk's operating profit in the next 12 months of a 5% movement in currency | Hedging period (months)1
USD | DKK 7,400 million | 12 |
CNY 2 | DKK 670 million | 12
CAD | DKK 490 million | 0
BRL | DKK 260 million | 0
JPY | DKK 210 million | 12 |

1) As of 31 December 2024.
2) Chinese yuan traded offshore (CNH) used as proxy when hedging Novo Nordisk’s CNY currency exposure.
The financial impact from foreign exchange hedging is included in Financial items (net).

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 19 of 35

INNOVATION AND THERAPEUTIC FOCUS
Diabetes care
Regulatory approvals for Ozempic® label expansion in the EU and US t o reflect data from the kidney outcomes trial FLOW
In December 2024, Novo Nordisk announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for an update of the Ozempic® label to reflect data from the kidney outcomes trial FLOW. For further information, please see the company announcement here: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915077 (The contents of the company's website do not form a part of this Form 6-K).
. Similarly, in January 2025, the Ozempic® label expansion update related to the FLOW trial was approved by the US Food and Drug Administration (FDA). In the FLOW trial, semaglutide 1.0 mg demonstrated a 24% reduction in the risk of kidney disease-related events in people with type 2 diabetes and chronic kidney disease. In the trial, semaglutide 1.0 mg appeared to have a safe and well-tolerated profile in line with previous semaglutide 1.0 mg trials.
Once-weekly IcoSema submitted for regulatory approval in China
In November 2024, Novo Nordisk submitted IcoSema, a once-weekly combination of basal insulin icodec and semaglutide, to the Centre for Drug Evaluation (CDE) for regulatory approval in China.
Update on regulatory submissions for Ozempic® in the EU and US to reflect data from the functional outcomes trial STRIDE
In December 2024 and January 2025, Novo Nordisk submitted a supplemental New Drug Application (sNDA) to the US FDA and a Type II variant application to the EMA, respectively, for Ozempic® for the indication of peripheral artery disease. The data are based on the STRIDE trial which achieved its primary objective by demonstrating a statistically significant and superior improvement in maximum walking distance of 13% for people treated with semaglutide 1.0 mg compared to placebo. In the trial, semaglutide 1.0 mg appeared to have a safe and well-tolerated profile in line with previous semaglutide 1.0 mg trials.
Update on regulatory milestones for oral semaglutide (Rybelsus®) in the EU and US
In December 2024 and January 2025, Novo Nordisk submitted a supplemental New Drug Application (sNDA) to the US FDA and a Type II variant application to the EMA, respectively, for Rybelsus® for the indication of reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack or non-fatal stroke) in people with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease. This is based on data from the SOUL trial which achieved its primary objective by demonstrating a statistically significant and superior reduction in major adverse cardiovascular events (MACE) of 14% for people treated with oral semaglutide compared to placebo. As part of standard of care, 49% of patients received SGLT2i at some point during the trial. In the trial, oral semaglutide appeared to have a safe and well-tolerated profile in line with previous oral semaglutide trials. Further, in January 2025, the US FDA granted a marketing authorisation of a formulation change application in the US to introduce 1.5 mg, 4 mg and 9 mg daily doses of or Rybelsus® equivalent to 3 mg, 7 mg and 14 mg doses, respectively.
Phase 2a trial with monlunabant in diabetic kidney disease completed
In November 2024, Novo Nordisk completed a phase 2 trial in participants with diabetic kidney disease treated with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. The trial investigated the efficacy and safety of a once-daily 10 mg and 25 mg dose of monlunabant compared to placebo on Urine Albumin-Creatinine ratio (uACR) after 16 weeks in 254 people with diabetic kidney disease. The trial did not meet its primary endpoint of a statistical significant improvement on uACR with monlunabant versus placebo. In the trial, the most common adverse events were gastrointestinal, with the vast majority being mild to moderate in severity. Reporting of mild to moderate neuropsychiatric side effects was more frequent with monlunabant compared to placebo. Following the completion of this phase 2 trial, monlunabant in kidney disease is being evaluated for further clinical development.
Phase 1 trial with glucose-sensitive insulin NN1644 initiated
In November 2024, Novo Nordisk initiated a phase 1 trial with a subcutaneously administrated glucose-sensitive insulin NN1644. The trial is investigating safety, tolerability, pharmacokinetics and pharmacodynamics of different doses of a glucose-sensitive insulin NN1644 in healthy volunteers and people with type 1 diabetes.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 20 of 35

Obesity care
Re-submission to the US FDA of the results from the Wegovy® STEP HFpEF trials
In January 2025, Novo Nordisk re-submitted the results from the HFpEF trials to FDA in the US with data from FLOW and SOUL included.
Next steps for oral semaglutide 25 mg in people with obesity or overweight
In June 2024, Novo Nordisk successfully completed OASIS 4, a phase 3b trial in the global OASIS programme. OASIS 4 was a 64-week, efficacy and safety trial comparing once-daily oral semaglutide 25 mg for weight management to placebo in 307 adults with obesity or overweight with one or more comorbidities. From a baseline bodyweight of 105.9 kg, oral semaglutide 25 mg achieved 16.6% weight loss compared to a 2.7% reduction with placebo in adults with obesity or overweight (if all participants adhered to treatment). When applying the treatment policy estimand, oral semaglutide 25 mg achieved 13.6% weight loss compared to 2.2% reduction with placebo. In the trial, oral semaglutide 25 mg appeared to have a safe and well-tolerated profile. Novo Nordisk expects to file for regulatory approval with the US FDA within the next few months.
Phase 3b trial (STEP UP) with semaglutide 7.2 mg in people with obesity successfully completed
In January 2025, Novo Nordisk announced headline results from STEP UP, a phase 3b trial in the global STEP programme. STEP UP is a 72-week efficacy and safety trial investigating subcutaneous semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered once weekly. When evaluating the effects of treatment if all people adhered to treatment from a mean baseline body weight of 113 kg, people treated with semaglutide 7.2 mg achieved a superior weight loss of 20.7% after 72 weeks compared to a reduction of 17.5% with semaglutide 2.4 mg and 2.4% with placebo. In the trial, semaglutide 7.2 mg appeared to have a safe and well-tolerated profile. For further information, please see the company announcement here: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915087 (The contents of the company's website do not form a part of this Form 6-K).
Phase 3b trial (STEP UP T2D) with semaglutide 7.2 mg in people with obesity and diabetes successfully completed
In January 2025, Novo Nordisk successfully completed STEP-UP T2D, a phase 3b trial in the global STEP programme. STEP-UP T2D was a 72-week trial investigating efficacy of semaglutide 7.2 mg compared to placebo, and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo, all administered subcutaneously once-weekly, in 512 adults with obesity and type 2 diabetes. The trial met its co-primary endpoints. From an overall baseline bodyweight of 110.1 kg, semaglutide 7.2 mg achieved 13.2% weight loss compared to 10.4% with semaglutide 2.4 mg and 3.9% with placebo (14.1% weight loss compared to a 10.7% and 3.6% reduction, respectively, if all people adhered to treatment). In the trial, semaglutide 7.2 mg appeared to have a safe and well-tolerated profile. The most common adverse events were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class.
CagriSema demonstrated superior weight loss in adults with obesity or overweight in the phase 3 trial, REDEFINE 1
In December 2024, Novo Nordisk announced headline results from REDEFINE 1, a 68-week efficacy and safety trial investigating subcutaneous CagriSema (a fixed dose combination of cagrilintide 2.4 mg and semaglutide 2.4 mg) compared to the individual components cagrilintide 2.4 mg, semaglutide 2.4 mg and placebo. After 68 weeks, if all people adhered to treatment and from a baseline bodyweight of 106.9 kg, CagriSema achieved a superior weight loss of 22.7% compared to a reduction of 11.8% with cagrilintide 2.4 mg, 16.1% with semaglutide 2.4 mg and 2.3% with placebo alone. In the trial, CagriSema, cagrilintide 2.4 mg and semaglutide 2.4 mg appeared to have a safe and well-tolerated profile. For further information, please see the company announcement here: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915082 (The contents of the company's website do not form a part of this Form 6-K)..
The results from the second pivotal phase 3 trial, REDEFINE 2, in adults with type 2 diabetes and either obesity or overweight are expected during the first quarter of 2025. To explore further weight loss potential of CagriSema, Novo Nordisk plans to initiate a new phase 3 trial in 2025. In order to secure supply chain readiness, Novo Nordisk now expects to file for the first regulatory approval of CagriSema during the first quarter of 2026.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 21 of 35

Novo Nordisk successfully completes phase 1b/2a trial with subcutaneous amycretin in people with overweight or obesity
In January 2025, Novo Nordisk announced headline results from a phase 1b/2a trial investigating the safety, tolerability, pharmacokinetics, and proof of concept after once-weekly subcutaneous administrations of amycretin in 125 people with overweight or obesity. The primary endpoint was treatment emergent adverse events. The safety profile of amycretin was consistent with incretin-based therapies. The most common adverse events with amycretin were gastrointestinal and the vast majority were mild to moderate in severity. When evaluating the effects of treatment if all people adhered to treatment from a mean baseline body weight of 92.7 kg, people treated with amycretin achieved an estimated body weight loss of 9.7% on 1.25 mg (20 weeks), 16.2% on 5 mg (28 weeks) and 22.0% on 20 mg (36 weeks). Based on the results, Novo Nordisk is now planning further clinical development of amycretin in adults with overweight or obesity. For further information, please see the company announcement here: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=915251#:~:text=Amycretin%20is%20a%20unimolecular%20long,for%20oral%20and%20subcutaneous%20administration (The contents of the company's website do not form a part of this Form 6-K).
Phase 1 trial with a tri-agonist (Triple) initiated
In December 2024, Novo Nordisk initiated a phase 1 trial with a once-weekly subcutaneous tri-agonist (Triple). The trial is investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of different doses of Triple in people with overweight or obesity.
Phase 1 trial with amylin 1213 initiated
In December 2024, Novo Nordisk initiated a phase 1 trial with once-weekly subcutaneous amylin 1213. The trial is investigating safety, tolerability, pharmacokinetics and pharmacodynamics of amylin 1213 in people with overweight or obesity.
Rare disease
Concizumab regulatory milestones within haemophilia
In December 2024, concizumab was approved in the US and EU for the treatment of haemophilia A and B with inhibitors. Concizumab was approved under the brand name Alhemo®. In January 2025, concizumab was submitted in the EU for the treatment of haemophilia A and B without inhibitors.
Cardiovascular & Emerging Therapy Areas
Phase 2 trial initiated with a once-weekly subcutaneous dual GIP/GLP-1 agonist in people with chronic kidney disease
In December 2024, Novo Nordisk initiated a phase 2 trial with a subcutaneous once-weekly dual GIP/GLP-1 agonist in approximately 450 people with chronic kidney disease, with or without type 2 diabetes and with overweight or obesity. The trial is investigating safety and efficacy of different doses of GIP/GLP-1.
Technology platforms
Phase 1 trial with DCR-XDH using the GalXC-Plus™ platform initiated
In December 2024, Novo Nordisk initiated a phase 1 trial with DCR-XDH using the GalXC-Plus™ platform. DCR-XDH is an siRNA, developed to treat gout with the goal of silencing xanthine dehydrogenase. The phase 1 trial, using the proprietary platform GalXC-Plus™, aims to address an intracellular target outside the liver and evaluate safety and tolerability in healthy volunteers with asymptomatic hyperuricemia.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 22 of 35

PURPOSE AND SUSTAINABILITY 1
ENVIRONMENT

ENVIRONMENTAL PERFORMANCE | Unit | 2024 | 2023 |  |  |  | % change 2024 to 2023
|  |  | 781 |  |  |  |
Total CO 2 e emissions | 1,000 tonnes CO 2 e | 2,261 | 1,836 |  |  |  | 23 | %
- Scope 1 CO 2 e emissions 1 | 1,000 tonnes CO 2 e | 85 | 78 |  |  |  | 9 | %
- Scope 2 CO 2 e emissions 2 | 1,000 tonnes CO 2 e | 16 | 15 |  |  |  | 7 | %
- Scope 3 CO 2 e emissions 3 | 1,000 tonnes CO 2 e | 2,160 | 1,743 |  |  |  | 24 | %
1. Scope 1: Direct CO 2 e emissions from sources that are owned or controlled by the Novo Nordisk Group. 2. Scope 2: Indirect emissions from purchased electricity, heat and steam. Market-based emissions are calculated based on CO 2 e emission factors from the previous year. 3. Scope 3: Indirect emissions from Novo Nordisk full value chain.

Emissions
Novo Nordisk aims to reach zero CO 2 e emissions from operations and transportation by 2030. Further, the aim is that goods and services from suppliers will be based on 100% sourced renewable power by 2030. In 2024, Novo Nordisk has reduced CO 2 e emissions from operations and transportation (Scope 1, 2 and partial Scope 3) by 38% compared to 2019. The reduction is driven by decarbonisation initiatives, including increased usage of renewable energy and biofuel as well as reduced business flights.
Compared to 2023, Scope 1 CO 2 e emissions increased by 9%, reflecting increased production volumes. This is partially countered by energy-saving initiatives.
Scope 2 CO 2 e emissions increased by 7% compared to 2023, mainly reflecting the expansion of facilities, partially countered by an increase in the usage of renewable energy sources.
Scope 3 CO 2 e emissions increased by 24% compared to 2023 due to increased investments in capital expenditure for property, plant and equipment.
SOCIAL

SOCIAL PERFORMANCE | Unit | 2024 | 2023 |  |  |  | % change 2024 to 2023 |  |  |  |  |  |  |
Patients |  |  |  |  |  |  |  |  |  |  |  |  |  |
Total numbers of patients reached | Estimate in millions 1 | 45.2 | 41.6 |  |  |  | 9 | % |  |  |  |  |  |  |
–Patients reached with Novo Nordisk's Diabetes care products | Estimate in millions 1 | 43.0 | 40.5 |  |  |  | 6 | % |  |  |  |  |  |  |
–Patients reached with Novo Nordisk's Obesity care products | Estimate in millions 1 | 2.2 | 1.1 |  |  |  | 100 | % |  |  |  |  |  |  |
Children reached through the Changing Diabetes® in Children programme | Number of children 2 | 64,743 | 52,249 |  |  |  | 24 | % |  |  |  |  |  |  |
Sustainable employer |  |  |  |  |  |  |  |  |  |  |  |  |  |
Gender in leadership positions 3 | Men:women | 53:47 | 54:46 |  |  |  | N/A |  |  |  |  |  |  |
Gender in senior leadership positions 4 | Men:women | 58:42 | 59:41 |  |  |  | N/A |  |  |  |  |  |  |
1. Calculated as a moving annual total. The estimated total number of full-year patients reached over a 12-month period. 2. Total cumulative number of children. The number of children reached with Diabetes care treatment through the Changing Diabetes® in Children programme since the initiation of the partnership in 2009. 3. Defined as team leaders, managers, directors, vice presidents, corporate vice presidents, senior vice presidents and executive management. 4. Defined as vice presidents, corporate vice presidents, senior vice presidents and executive management. |  |  |  |  |  |  |

1 The impact of the Catalent acquisition has been deemed immaterial and is not included in our Sustainability statement.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 23 of 35

Patients
The number of people reached with Novo Nordisk products, across Diabetes and Obesity care, was 45.2 million at the end of 2024. This represents a net increase of 3.6 million patients compared to the end of 2023.
The Changing Diabetes® in Children programme aims to reach 100,000 children by 2030. By the end of 2024, more than 64,743 children were reached with Diabetes care treatment, an increase of 24% compared to the end 2023.
Sustainable employer
Novo Nordisk aspires to be a sustainable employer. In 2021, two aspirational gender diversity targets were launched; a chieve a balanced gender representation across all managerial levels and achieve a minimum of 45% women and a minimum of 45% men in senior leadership positions by the end of 2025.
At the end of 2024, 47% of all leaders were women and 42% of leaders in senior leadership positions were women, compared to 46% and 41%, respectively, at the end of 2023.
The number of full-time employees at the end of 2024 increased by 20% compared to 12 months ago. The total number of full-time employees was 76,302 2. The increase is mainly driven by Product Supply.
International crises, geopolitical tensions and natural disasters
Novo Nordisk is committed to supporting the wellbeing of our employees and ensuring uninterrupted access to essential medicines during humanitarian crises. Our priorities include safeguarding our workforce and collaborating with humanitarian organisations to provide critical medications to affected regions.
In recent crises, including the Israel-Hamas conflict and Russia's invasion of Ukraine, we have maintained essential supplies to ensure patients can continue their treatments, underscoring our dedication to supporting communities in need.
Corporate Governance
Long-term incentive programme 2025
The Board of Directors has established a long-term incentive programme for 2025 covering Executive Management and, in
line with previous years, a number of mid to senior managers (in total approximately 3,600 employees) with a three-year
performance period (2025-2027). The measures are linked to the Strategic Aspirations 2025. Within Purpose &
Sustainability measures are mainly linked to social and environmental activities and within Innovation & Therapeutic Focus,
the measures include key R&D activities. For Commercial Execution, the measure is sales growth and for Financials, the
measure is operating profit growth. Around 1.6 million Novo Nordisk B shares may be allocated at target (at maximum
target achievement, the number of shares is around 4.2 million), and the value at launch of the programme will be based
on the average share price for Novo Nordisk B shares on Nasdaq Copenhagen in the 15 days trading window (5 February
to 19 February 2025) following the release of the Annual Report for 2024. It is currently estimated that the value at target is
approximately DKK 1 billion.
Remuneration Report 2024
Novo Nordisk has prepared a separate Remuneration Report describing the remuneration awarded or due during 2024 to
the Board members and Executives as registered with the Danish Business Authority. The Remuneration Report will be
submitted to the Annual General Meeting for an advisory vote. The Remuneration Report is available at novonordisk.com.
2 This figure includes the new employees related to the Catalent acquisition.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 24 of 35

LEGAL MATTERS
Update on ANDAs with the FDA relating to semaglutide
Novo Nordisk has received notifications from several manufacturers that they have filed ANDAs with the FDA for generic versions of Ozempic®, Wegovy® and Rybelsus®, respectively. Novo Nordisk has filed complaints for patent infringement against these manufacturers. Novo Nordisk has now reached settlement agreements with all of these manufacturers concerning Ozempic®. The terms of the agreements are confidential. These agreements are reviewed by the U.S. Federal Trade Commission and the U.S. Department of Justice. Novo Nordisk does not expect these matters to have a material impact on Novo Nordisk’s financial position, operating profit or cash flow.
Securities class-action lawsuit filed against Novo Nordisk A/S
On 24 January 2025, a class-action lawsuit was filed against Novo Nordisk A/S, Chief Executive Officer Lars Fruergaard Jørgensen and Executive Vice President, Development Martin Holst Lange in the United States District Court for the District of New Jersey by a proposed class of purchasers of Novo Nordisk American Depository Receipts (ADRs) between 2 November 2022 and 19 December 2024. The lawsuit relates to REDEFINE 1 and alleges that the company failed to disclose or otherwise misled investors as to the nature of the dosages provided to patients in the study and that the company misleadingly exhibited confidence in its expected 25% average weight loss outcome. Novo Nordisk does not expect the litigation to have a material impact on Novo Nordisk’s financial position, operating profit or cash flow.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 25 of 35

STATEMENT BY THE BOARD OF DIRECTORS AND EXECUTIVE MANAGEMENT
The Board of Dir ectors and Executive Management have today considered and approved the Annual Report 2024 of Novo Nordisk A/S for the financial year 1 January 2024 - 31 December 2024, including the audited consolidated financial statements and reviewed Sustainability statement. The Board of Directors and Executive Management have also today approved this financial report containing condensed financial information and condensed sustainability information for 2024.
The condensed financial information in this financial report has been prepared in accordance with the recognition and measurement requirements in the IFRS Accounting Standards as adopted by the EU, the accounting policies as applied in the audited consolidated financial statements of 2024 and additional disclosure requirements for listed companies.
The condensed sustainability information in this financial report has been prepared in accordance with the ESRS and the accounting policies as applied in the reviewed Sustainability statement.
In our opinion, the accounting policies used are appropriate, and the overall presentation of this financial report is
adequate. Furthermore, in our opinion, this financial report includes a true and fair view of the financial position at 31 December 2024 as well as of the results of the operations, the cash flows and the sustainability performance for the financial year 1 January - 31 December 2024.
Bagsv ærd, 5 February 2025

Executive Management: |  |
Lars Fruergaard Jørgensen President and CEO | Karsten Munk Knudsen CFO |
Board of Directors: |  |
Helge Lund Chair | Henrik Poulsen Vice chair | Elisabeth Dahl Christensen
Laurence Debroux | Andreas Fibig | Sylvie Grégoire
Liselotte Hyveled | Mette Bøjer Jensen | Kasim Kutay
Christina Law | Martin Mackay | Thomas Rantzau

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 26 of 35

About Novo Nordisk
Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs abou t 76,300 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, X, LinkedIn and YouTube.

Financial Calendar |  |
27 March 2025 | Annual General meeting |
7 May 2025 | Financial results for the first three months of 2025 |
6 August 2025 | Financial results for the first six months of 2025 |
5 November 2025 | Financial results for the first nine months of 2025 |

Contacts for further information |
Media: |
Ambre James-Brown +45 3079 9289 abmo@novonordisk.com | Liz Skrbkova (US) +1 609 917 0632 lzsk@novonordisk.com
Investors: |
Jacob Martin Wiborg Rode +45 3075 5956 jrde@novonordisk.com | Sina Meyer +45 3079 6656 azey@novonordisk.com
Ida Schaap Melvold +45 3077 5649 idmg@novonordisk.com | Frederik Taylor Pitter (US) +1 609 613 0568 fptr@novonordisk.com
Max Ung +45 3077 6414 mxun@novonordisk.com |

Forward-looking statements
Novo Nordisk’s statutory Annual Report 2024, Form 20-F, any quarterly financial reports, and written information released, shown, or oral statements made, to the public in the future by or on behalf of Novo Nordisk, may contain certain forward-looking statements relating to the operating, financial and sustainability performance and results of Novo Nordisk and/or the industry in which it operates. Forward-looking statements can be identified by the fact that they do not relate to historical or current facts and include guidance. Words such as ‘believe’, ‘expect’, ‘may’, ‘will’, ‘plan’, ‘strategy’, ‘transition plan’, ‘prospect’, ‘foresee’, ‘estimate’, ‘project’, ‘anticipate’, ‘can’, ‘intend’, ‘target’ and other words and terms of similar meaning in connection with any discussion of future operating, financial or sustainability performance identify forward-looking statements. Examples of such forward-looking statements include, but are not limited to:
Statements of targets, future guidance, (transition) plans, objectives or goals for future operations, including those related to operating, financial and sustainability matters, Novo Nordisk’s products, product research, product development, product introductions and product approvals as well as cooperation in relation thereto;
•Statements containing projections of or targets for revenues, costs, income (or loss), earnings per share, capital expenditures, dividends, capital structure, net financials and other financial measures;
•Statements regarding future economic performance, future actions and outcome of contingencies such as legal proceedings; and
•Statements regarding the assumptions underlying or relating to such statements.
•These statements are based on current plans, estimates, opinions, views and projections. Although Novo Nordisk believes that the expectation reflected in such forward-looking statements are reasonable, there can be no assurance that such expectation will prove to be correct. By their very nature, forward-looking statements involve risks, uncertainties and assumptions, both general and specific, and actual results may differ materially from those contemplated, expressed or implied by any forward-looking statement.
Factors that may affect future results include, but are not limited to, global as well as local political, economic and environmental conditions, such as interest rate and currency exchange rate fluctuations or climate change, delay or failure of projects related to research and/or development, unplanned loss of patents, interruptions of supplies and production, including as a result of interruptions or delays affecting supply chains on which Novo Nordisk relies, shortages of supplies, including energy supplies, product recalls, unexpected contract breaches or terminations, government- mandated or market-driven price decreases for Novo Nordisk’s products, introduction of competing products, reliance on information technology including the risk of cybersecurity breaches, Novo Nordisk’s ability to successfully market current and new products, exposure to product liability and legal proceedings and investigations, changes in governmental laws and related interpretation thereof, including on reimbursement, intellectual property protection and regulatory controls on testing, approval, manufacturing and marketing, and taxation changes, including changes in tariffs and duties, perceived or actual failure to adhere to ethical marketing practices, investments in and divestitures of domestic and foreign companies, unexpected growth in costs and expenses, strikes and other labour market disputes, failure to recruit and retain the right employees, failure to maintain a culture of compliance, epidemics, pandemics or other public health crises, the effects of domestic or international crises, civil unrest, war or other conflict and factors related to the foregoing matters and other factors not specifically identified herein.
For an overview of some, but not all, of the risks that could adversely affect Novo Nordisk’s results or the accuracy of forward-looking statements in the Annual Report 2024, reference is made to the overview of risk factors in ‘Risks’ of the Annual Report 2024.
None of Novo Nordisk or its subsidiaries or any such person's officers, or employees accept any responsibility for the future accuracy of the opinions expressed in the Annual Report 2024, Form 20-F, any quarterly financial reports, and written information released, shown, or oral statements made, to the public in the future by or on behalf of Novo Nordisk or the actual occurrence of the forecasted developments.
Unless required by law, Novo Nordisk has no duty and undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 27 of 35

APPENDIX 1: QUARTERLY NUMBERS IN DKK

(Amounts in DKK million, except number of full-time equivalent employees, earnings per share and number of shares outstanding).
|  |  |  |  |  |  |  |  |  |  | % change
| 2024 |  | 2023 |  | Q4 2024 vs.
| Q4 | Q3 | Q2 | Q1 |  | Q4 | Q3 | Q2 | Q1 |  | Q4 2023
Net sales | 85,683 | 71,311 | 68,060 | 65,349 |  | 65,863 | 58,731 | 54,300 | 53,367 |  | 30 | %
Gross profit | 72,659 | 60,003 | 57,786 | 55,433 |  | 55,849 | 49,018 | 46,444 | 45,185 |  | 30 | %
Gross margin | 84.8% | 84.1% | 84.9% | 84.8% |  | 84.8% | 83.5% | 85.5% | 84.7% |  |
Sales and distribution costs | (18,701) | (15,210) | (14,934) | (13,256) |  | (17,170) | (12,819) | (14,342) | (12,412) |  | 9 | %
Percentage of sales | 21.8% | 21.3% | 21.9% | 20.3% |  | 26.1% | 21.8% | 26.4% | 23.3% |  |
Research and development costs 1 | (13,802) | (9,488) | (16,166) | (8,606) |  | (10,460) | (8,128) | (7,127) | (6,728) |  | 32 | %
Percentage of sales | 16.1% | 13.3% | 23.8% | 13.2% |  | 15.9% | 13.8% | 13.1% | 12.6% |  |
Administrative costs | (1,580) | (1,382) | (1,157) | (1,157) |  | (1,456) | (1,256) | (1,072) | (1,071) |  | 9 | %
Percentage of sales | 1.8% | 1.9% | 1.7% | 1.8% |  | 2.2% | 2.1% | 2.0% | 2.0% |  |
Other operating income and expenses | (1,839) | (101) | 405 | (568) |  | 3 | 98 | (15) | 33 |  | N/A
Operating profit (EBIT) | 36,737 | 33,822 | 25,934 | 31,846 |  | 26,766 | 26,913 | 23,888 | 25,007 |  | 37 | %
Operating margin | 42.9% | 47.4% | 38.1% | 48.7% |  | 40.6% | 45.8% | 44.0% | 46.9% |  |
Financial income | 3,913 | (821) | 960 | 2,146 |  | (944) | 3,318 | (281) | 852 |  | N/A
Financial expenses | (5,093) | 1,383 | (1,562) | (2,074) |  | 1,798 | (2,168) | 647 | (1,122) |  | N/A
Financial items (net) | (1,180) | 562 | (602) | 72 |  | 854 | 1,150 | 366 | (270) |  | (238 | %)
Profit before income taxes | 35,557 | 34,384 | 25,332 | 31,918 |  | 27,620 | 28,063 | 24,254 | 24,737 |  | 29 | %
Income taxes | (7,327) | (7,083) | (5,282) | (6,511) |  | (5,657) | (5,585) | (4,826) | (4,923) |  | 30 | %
Net profit | 28,230 | 27,301 | 20,050 | 25,407 |  | 21,963 | 22,478 | 19,428 | 19,814 |  | 29 | %
Depreciation, amortisation and impairment losses 1 | 5,198 | 2,150 | 8,845 | 2,914 |  | 2,992 | 2,525 | 2,177 | 1,719 |  | 74 | %
Capital expenditure (PP&E) | 16,101 | 12,119 | 10,470 | 8,474 |  | 9,407 | 5,828 | 5,878 | 4,693 |  | 71 | %
Net cash flows from operating activities | 12,301 | 43,850 | 50,503 | 14,314 |  | 9,551 | 40,966 | 28,577 | 29,814 |  | 29 | %
EBITDA | 41,935 | 35,972 | 34,779 | 34,760 |  | 29,758 | 29,438 | 26,065 | 26,726 |  | 41 | %
Free cash flow | (86,467) | 30,451 | 36,289 | 5,020 |  | (7,250) | 30,039 | 20,773 | 24,764 |  | N/A
Total assets | 465,795 | 397,441 | 369,383 | 298,921 |  | 314,486 | 300,101 | 280,753 | 250,025 |  | 48 | %
Total equity | 143,486 | 120,522 | 112,522 | 98,911 |  | 106,561 | 92,991 | 90,473 | 79,874 |  | 35 | %
Equity ratio | 30.8% | 30.3% | 30.5% | 33.1% |  | 33.9% | 31.0% | 32.2% | 31.9% |  |
Full-time equivalent employees end of period | 76,302 | 71,880 | 69,260 | 66,015 |  | 63,370 | 61,412 | 59,337 | 57,089 |  | 20 | %
Basic earnings per share/ADR (in DKK) | 6.34 | 6.13 | 4.50 | 5.70 |  | 4.92 | 5.02 | 4.33 | 4.40 |  | 29 | %
Diluted earnings per share/ADR (in DKK) | 6.34 | 6.12 | 4.49 | 5.68 |  | 4.91 | 5.00 | 4.32 | 4.39 |  | 29 | %
Average number of shares outstanding (million) | 4,446.2 | 4,452.3 | 4,457.7 | 4,459.6 |  | 4,464.7 | 4,476.9 | 4,490.4 | 4,499.2 |  | 0 | %
Average number of diluted shares outstanding (million) | 4,455.5 | 4,460.5 | 4,465.4 | 4,470.5 |  | 4,477.4 | 4,489.0 | 4,502.6 | 4,513.2 |  | 0 | %
Sales by business segment: |  |  |  |  |  |  |  |  |  |  |
Total GLP-1 | 42,173 | 34,935 | 37,035 | 34,982 |  | 37,761 | 30,635 | 27,925 | 26,811 |  | 12 | %
Long-acting insulin | 5,158 | 4,035 | 4,737 | 5,165 |  | 3,726 | 3,692 | 3,354 | 4,133 |  | 38 | %
Premix insulin | 2,867 | 2,518 | 2,436 | 2,968 |  | 2,123 | 2,219 | 2,456 | 2,776 |  | 35 | %
Fast-acting insulin | 6,017 | 4,150 | 3,868 | 4,487 |  | 4,142 | 3,808 | 3,511 | 4,488 |  | 45 | %
Human insulin | 1,845 | 1,806 | 1,571 | 1,745 |  | 1,989 | 1,626 | 1,967 | 2,012 |  | (7 | %)
Total insulin | 15,887 | 12,509 | 12,612 | 14,365 |  | 11,980 | 11,345 | 11,288 | 13,409 |  | 33 | %
Other Diabetes care | 512 | 492 | 533 | 583 |  | 322 | 594 | 667 | 729 |  | 59 | %
Total Diabetes care | 58,572 | 47,936 | 50,180 | 49,930 |  | 50,063 | 42,574 | 39,880 | 40,949 |  | 17 | %
Wegovy® | 19,866 | 17,304 | 11,659 | 9,377 |  | 9,614 | 9,648 | 7,518 | 4,563 |  | 107 | %
Saxenda® | 1,540 | 1,497 | 2,245 | 1,658 |  | 1,615 | 2,607 | 2,788 | 3,279 |  | (5 | %)
Total Obesity care | 21,406 | 18,801 | 13,904 | 11,035 |  | 11,229 | 12,255 | 10,306 | 7,842 |  | 91 | %
Diabetes and Obesity care total | 79,978 | 66,737 | 64,084 | 60,965 |  | 61,292 | 54,829 | 50,186 | 48,791 |  | 30 | %
Rare blood disorders | 3,398 | 2,988 | 2,864 | 2,888 |  | 2,934 | 2,957 | 2,836 | 3,049 |  | 16 | %
Rare endocrine disorders | 1,923 | 1,227 | 730 | 1,113 |  | 1,264 | 542 | 902 | 1,128 |  | 52 | %
Other Rare disease | 384 | 359 | 382 | 383 |  | 373 | 403 | 376 | 399 |  | 3 | %
Rare disease total | 5,705 | 4,574 | 3,976 | 4,384 |  | 4,571 | 3,902 | 4,114 | 4,576 |  | 25 | %
Sales by geographic segment: |  |  |  |  |  |  |  |  |  |  |
North America Operations | 55,364 | 42,598 | 40,930 | 39,280 |  | 42,621 | 35,048 | 29,663 | 29,297 |  | 30 | %
- The US | 52,372 | 39,844 | 38,404 | 36,782 |  | 40,067 | 32,936 | 27,209 | 27,322 |  | 31 | %
International Operations | 30,319 | 28,713 | 27,130 | 26,069 |  | 23,242 | 23,683 | 24,637 | 24,070 |  | 30 | %
- EMEA | 16,759 | 14,736 | 14,581 | 14,326 |  | 12,706 | 12,563 | 12,856 | 12,742 |  | 32 | %
- Region China | 4,324 | 4,708 | 4,963 | 4,506 |  | 3,418 | 4,341 | 4,467 | 4,461 |  | 27 | %
- Rest of World | 9,236 | 9,269 | 7,586 | 7,237 |  | 7,118 | 6,779 | 7,314 | 6,867 |  | 30 | %
Segment operating profit: |  |  |  |  |  |  |  |  |  |  |
Diabetes and Obesity care | 36,044 | 33,473 | 26,984 | 31,218 |  | 26,032 | 26,721 | 22,707 | 24,163 |  | 38 | %
Rare disease | 693 | 349 | (1,050) | 628 |  | 734 | 192 | 1,181 | 844 |  | (6 | %)

1) Research and development expenses include an impairment loss of DKK 5.7 billion in the second quarter of 2024 related to ocedurenone. The impairment loss is recognised in the segment Diabetes and Obesity.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 28 of 35

APPENDIX 2: INCOME STATEMENT AND STATEMENT OF COMPREHENSIVE INCOME

DKK million | 2024 |  | 2023 |  |  |  |
Income statement |  |  |  |  |  |  |
Net sales | 290,403 |  | 232,261 |  |  |  |
Cost of goods sold | (44,522) |  | (35,765) |  |  |  |
Gross profit | 245,881 |  | 196,496 |  |  |  |
Sales and distribution costs | (62,101) |  | (56,743) |  |  |  |
Research and development costs 1 | (48,062) |  | (32,443) |  |  |  |
Administrative costs | (5,276) |  | (4,855) |  |  |  |
Other operating income and expenses | (2,103) |  | 119 |  |  |  |
Operating profit | 128,339 |  | 102,574 | 102574000000 |  |  |
Financial income | 6,198 |  | 2,945 |  |  |  |
Financial expenses | (7,346) |  | (845) |  |  |  |
Profit before income taxes | 127,191 |  | 104,674 |  |  |  |
Income taxes | (26,203) |  | (20,991) |  |  |  |
NET PROFIT | 100,988 |  | 83,683 | 83683000000 |  |  |
Basic earnings per share (DKK) | 22.67 |  | 18.67 |  |  |  |
Diluted earnings per share (DKK) | 22.63 |  | 18.62 |  |  |  |
Segment Information |  |  |  |  |  |  |
Segment sales: |  |  |  |  |  |  |
Diabetes and Obesity care | 271,764 |  | 215,098 |  |  |  |
Rare disease | 18,639 |  | 17,163 |  |  |  |
Segment operating profit: |  |  |  |  |  |  |
Diabetes and Obesity care | 127,719 |  | 99,623 |  |  |  |
Operating margin | 47.0% |  | 46.3% |  |  |  |
Rare disease | 620 |  | 2,951 |  |  |  |
Operating margin | 3.3% |  | 17.2% |  |  |  |
Total segment operating profit | 128,339 |  | 102,574 |  |  |  |
Statement of comprehensive income |  |  |  |  |  |  |
Net profit | 100,988 |  | 83,683 |  |  |  |
Other comprehensive income |  |  |  |  |  |  |
Remeasurements of defined benefit obligations | (119) |  | 13 |  |  |  |
Items that will not be reclassified subsequently to the income statement | (119) |  | 13 |  |  |  |
Exchange rate adjustments of investments in subsidiaries | 3,096 |  | (1,404) |  |  |  |
Cash flow hedges: |  |  |  |  |  |  |
Realisation of previously deferred (gains)/losses | (1,612) |  | (1,026) |  |  |  |
Deferred gains/(losses) related to acquisition of businesses | 1,154 |  | — |  |  |  |
Deferred gains/(losses) on hedges open at year-end | (5,763) |  | 1,612 |  |  |  |
Tax and other items | 1,343 |  | (355) |  |  |  |
Items that will be reclassified subsequently to the income statement | (1,782) |  | (1,173) |  |  |  |
Other comprehensive income | (1,901) |  | (1,160) |  |  |  |
TOTAL COMPREHENSIVE INCOME | 99,087 |  | 82,523 |  |  |  |

1) Research and development expenses include an impairment loss of DKK 5.7 billion in the second quarter of 2024 related to ocedurenone. The impairment loss is recognised in the segment Diabetes and Obesity.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 29 of 35

APPENDIX 3: CASH FLOW STATEMENT

DKK million | 2024 |  | 2023
Net profit | 100,988 |  |  | 83,683 |
Adjustment for non-cash items: |  |  |
Income taxes in the income statement | 26,203 |  |  | 20,991 |
Depreciation, amortisation and impairment losses | 19,107 |  |  | 9,413 |
Other non-cash items | 15,029 |  |  | 33,517 |
Change in working capital | (11,995) |  |  | (13,380) |
Interest received | 1,884 |  |  | 1,072 |
Interest paid | (612) |  |  | (491) |
Income taxes paid | (29,636) |  |  | (25,897) |
Net cash flows from operating activities | 120,968 |  |  | 108,908 |
Purchase of intangible assets | (4,145) |  |  | (13,090) |
Purchase of property, plant and equipment | (47,164) |  |  | (25,806) |
Cash used for acquisition of businesses | (82,163) |  |  | — |
Proceeds from other financial assets | — |  |  | 33 |
Purchase of other financial assets | (786) |  |  | (271) |
Purchase of marketable securities | (19,028) |  |  | (13,018) |
Sale of marketable securities | 24,391 |  |  | 8,260 |
Net cash flows from investing activities | (128,895) |  |  | (43,892) |
Purchase of treasury shares | (20,181) |  |  | (29,924) |
Dividends paid | (44,140) |  |  | (31,767) |
Proceeds from borrowings | 79,391 |  |  | — |
Repayment of borrowings | (6,335) |  |  | (1,467) |
Net cash flows from financing activities | 8,735 |  |  | (63,158) |
Net cash generated from activities | 808 |  |  | 1,858 |
Cash and cash equivalents at the beginning of the year | 14,392 |  |  | 12,653 |
Exchange gain/(loss) on cash and cash equivalents | 455 |  |  | (119) |
Cash and cash equivalents at the end of the year | 15,655 |  |  | 14,392 |

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 30 of 35

APPENDIX 4: BALANCE SHEET

DKK million | 31 Dec 2024 |  | 31 Dec 2023
ASSETS |  |  |
Intangible assets | 111,090 |  |  | 60,406 |
Property, plant and equipment | 162,488 |  |  | 90,961 |
Investments in associated companies | 400 |  |  | 410 |
Deferred income tax assets | 24,627 |  |  | 20,380 |
Other receivables and prepayments | 4,016 |  |  | 1,430 |
Other financial assets | 2,277 |  |  | 1,253 |
TOTAL NON-CURRENT ASSETS | 304,898 |  |  | 174,840 |
Inventories | 40,849 |  |  | 31,811 |
Trade receivables | 71,949 |  |  | 64,770 |
Tax receivables | 2,853 |  |  | 2,423 |
Other receivables and prepayments | 12,612 |  |  | 8,068 |
Marketable securities | 10,653 |  |  | 15,838 |
Derivative financial instruments | 6,326 |  |  | 2,344 |
Cash at bank | 15,655 |  |  | 14,392 |
TOTAL CURRENT ASSETS | 160,897 |  |  | 139,646 |
TOTAL ASSETS | 465,795 |  |  | 314,486 |
EQUITY AND LIABILITIES |  |  |
Share capital | 446 |  |  | 451 |
Treasury shares | (2) |  |  | (5) |
Retained earnings | 144,448 |  |  | 104,839 |
Other reserves | (1,406) |  |  | 1,276 |
TOTAL EQUITY | 143,486 |  |  | 106,561 |
Borrowings | 89,674 |  |  | 20,528 |
Deferred income tax liabilities | 5,426 |  |  | 10,162 |
Retirement benefit obligations | 903 |  |  | 742 |
Other liabilities | 23 |  |  | 189 |
Provisions | 8,755 |  |  | 6,649 |
Total non-current liabilities | 104,781 |  |  | 38,270 |
Borrowings | 13,113 |  |  | 6,478 |
Trade payables | 28,846 |  |  | 25,606 |
Tax payables | 9,716 |  |  | 7,116 |
Other liabilities | 37,993 |  |  | 28,705 |
Derivative financial instruments | 7,531 |  |  | 1,272 |
Provisions | 120,329 |  |  | 100,478 |
Total current liabilities | 217,528 |  |  | 169,655 |
TOTAL LIABILITIES | 322,309 |  |  | 207,925 |
TOTAL EQUITY AND LIABILITIES | 465,795 |  |  | 314,486 |

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 31 of 35

APPENDIX 5: EQUITY STATEMENT

DKK million | Share capital | Treasury shares | Retained earnings |  |  |  | Other reserves |  | Total
2024 |  |  |  |  |  |  |  |  |
Balance at the beginning of the year | 451 |  | (5) |  | 104,839 |  |  |  |  | 1,276 |  |  | 106,561 |
Net profit |  |  | 100,988 |  |  |  |  |  |  | 100,988 |
Other comprehensive income |  |  | (119) |  |  |  |  | (1,782) |  |  | (1,901) |
Total comprehensive income |  |  | 100,869 |  |  |  |  | (1,782) |  |  | 99,087 |
Transfer of cash flow hedge reserve to intangible assets |  |  |  |  |  |  | (900) |  |  | (900) |
Transactions with owners: |  |  |  |  |  |  |  |  |
Dividends |  |  | (44,140) |  |  |  |  |  |  | (44,140) |
Share-based payments |  |  | 2,289 |  |  |  |  |  |  | 2,289 |
Purchase of treasury shares |  | (2) |  | (20,179) |  |  |  |  |  |  | (20,181) |
Reduction of the B share capital | (5) |  | 5 |  |  |  |  |  |  |  | — |
Tax related to transactions with owners |  |  | 770 |  |  |  |  |  |  | 770 |
Balance at the end of the year | 446 |  | (2) |  | 144,448 |  |  |  |  | (1,406) |  |  | 143,486 |
At the end of the year propo sed final dividends (not yet declared) of DKK 35,100 million (DKK 7.90 per share of DKK 0.10) are included in Retained earnings. No dividend is declared on treasury shares.
DKK million | Share capital | Treasury shares | Retained earnings |  |  |  | Other reserves |  | Total
2023 |  |  |  |  |  |  |  |  |
Balance at the beginning of the year | 456 |  | (6) |  | 80,587 |  |  |  |  | 2,449 |  |  | 83,486 |
Net profit |  |  | 83,683 |  |  |  |  |  |  | 83,683 |
Other comprehensive income |  |  | 13 |  |  |  |  | (1,173) |  |  | (1,160) |
Total comprehensive income |  |  | 83,696 |  |  |  |  | (1,173) |  |  | 82,523 |
Transactions with owners: |  |  |  |  |  |  |  |  |
Dividends |  |  | (31,767) |  |  |  |  |  |  | (31,767) |
Share-based payments |  |  | 2,149 |  |  |  |  |  |  | 2,149 |
Purchase of treasury shares |  | (4) |  | (29,920) |  |  |  |  |  |  | (29,924) |
Reduction of the B share capital | (5) |  | 5 |  |  |  |  |  |  |  | — |
Tax related to transactions with owners |  |  | 94 |  |  |  |  |  |  | 94 |
Balance at the end of the year | 451 |  | (5) |  | 104,839 |  |  |  |  | 1,276 |  |  | 106,561 |
At the end of the year, proposed final dividends of DKK 28,557 million (DKK 6.40 per share of DKK 0.10) are included in Retained earnings. No dividend is declared on treasury shares.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 32 of 35

APPENDIX 6: SALES SPLIT PER AREA

Q4 2024 sales split per area |  |  |  |  |  |  |
DKK million | Total | North America Operations | The US | International Operations | EMEA | Region China | Rest of World
Diabetes and Obesity care segment |  |  |  |  |  |  |
| Injectable GLP-1 | 35,256 | 27,154 | 25,261 | 8,102 | 4,980 | 1,179 | 1,943
| % change at CER | 10% | 10% | 11% | 10% | 31% | (7%) | (13%)
|  | Ozempic® | 33,853 | 26,601 | 24,735 | 7,252 | 4,653 | 1,015 | 1,584
|  | % change at CER | 12% | 13% | 13% | 12% | 31% | (2%) | (16%)
|  | Victoza® | 1,403 | 553 | 526 | 850 | 327 | 164 | 359
|  | % change at CER | (22%) | (42%) | (40%) | (1%) | 20% | (30%) | 0%
| Rybelsus® | 6,917 | 3,192 | 3,116 | 3,725 | 2,025 | 360 | 1,340
| % change at CER | 18% | (17%) | (16%) | 82% | 69% | 0% | 65%
| Total GLP-1 | 42,173 | 30,346 | 28,377 | 11,827 | 7,005 | 1,539 | 3,283
| % change at CER | 12% | 7% | 7% | 26% | 40% | 19% | 7%
| Long-acting insulin | 5,158 | 1,813 | 1,643 | 3,345 | 1,952 | 767 | 626
| % change at CER | 40% | 92% | 111% | 22% | 15% | 102% | (3%)
|  | Awiqli® | 10 | 2 | — | 8 | 2 | 6 | —
|  | % change at CER | — | — | — | — | — | — | —
|  | Tresiba® | 2,735 | 1,107 | 952 | 1,628 | 976 | 253 | 399
|  | % change at CER | 45% | 160% | 241% | 12% | 18% | 21% | (3%)
|  | Xultophy® | 1,274 | 77 | 76 | 1,197 | 584 | 444 | 169
|  | % change at CER | 64% | 16% | 16% | 68% | 24% | 386% | 17%
|  | Levemir® | 1,139 | 627 | 615 | 512 | 390 | 64 | 58
|  | % change at CER | 11% | 39% | 42% | (11%) | (4%) | (21%) | (36%)
| Premix insulin | 2,867 | 281 | 278 | 2,586 | 673 | 1,130 | 783
| % change at CER | 33% | 0% | 0% | 18% | 10% | 17% | 27%
|  | Ryzodeg® | 1,346 | — | — | 1,346 | 162 | 764 | 420
|  | % change at CER | 48% | — | — | 48% | 22% | 68% | 29%
|  | NovoMix® | 1,521 | 281 | 278 | 1,240 | 511 | 366 | 363
|  | % change at CER | 23% | 0% | 0% | (4%) | 6% | (29%) | 25%
| Fast-acting insulin | 6,017 | 3,305 | 3,261 | 2,712 | 1,821 | 303 | 588
| % change at CER | 45% | 108% | 113% | 6% | 7% | (9%) | 13%
|  | Fiasp® | 343 | (92) | (104) | 435 | 353 | — | 82
|  | % change at CER | (45%) | (141%) | (149%) | 8% | 2% | — | 40%
|  | NovoRapid® | 5,674 | 3,397 | 3,365 | 2,277 | 1,468 | 303 | 506
|  | % change at CER | 62% | 149% | 155% | 6% | 9% | (9%) | 10%
| Human insulin | 1,845 | 525 | 515 | 1,320 | 417 | 170 | 733
| % change at CER | 11% | 73% | 77% | (2%) | (7%) | (41%) | 17%
| Total insulin | 15,887 | 5,924 | 5,697 | 9,963 | 4,863 | 2,370 | 2,730
| % change at CER | 36% | 112% | 123% | 13% | 9% | 20% | 13%
| Other Diabetes care 1 | 512 | 62 | 51 | 450 | 169 | 174 | 107
| % change at CER | (13%) | (48%) | (51%) | (4%) | (6%) | (9%) | 7%
| Total Diabetes care | 58,572 | 36,332 | 34,125 | 22,240 | 12,037 | 4,083 | 6,120
| % change at CER | 17% | 16% | 17% | 19% | 25% | 18% | 10%
| Wegovy® | 19,866 | 15,623 | 15,143 | 4,243 | 2,624 | 30 | 1,589
| % change at CER | 107% | 81% | 75% | 329% | 159% | — | —
| Saxenda® | 1,540 | 411 | 298 | 1,129 | 576 | 24 | 529
| % change at CER | (3%) | 26% | 106% | (10%) | (18%) | 41% | (1%)
| Total Obesity care | 21,406 | 16,034 | 15,441 | 5,372 | 3,200 | 54 | 2,118
| % change at CER | 91% | 79% | 75% | 139% | 86% | 224% | 295%
| Diabetes and Obesity care total | 79,978 | 52,366 | 49,566 | 27,612 | 15,237 | 4,137 | 8,238
| % change at CER | 31% | 30% | 31% | 32% | 34% | 19% | 35%
Rare disease segment |  |  |  |  |  |  |
| Rare blood disorders 2 | 3,398 | 1,516 | 1,446 | 1,882 | 1,072 | 151 | 659
| % change at CER | 16% | (1%) | (2%) | 35% | 17% | 0% | 44%
|  | Haemophilia A | 670 | 129 | 126 | 541 | 328 | 79 | 134
|  | % change at CER | 29% | 130% | 128% | 17% | 3% | 0% | (18%)
|  | Haemophilia B | 378 | 196 | 151 | 182 | 126 | 3 | 53
|  | % change at CER | 15% | 24% | 18% | 7% | 9% | (25%) | 6%
|  | NovoSeven® | 2,226 | 1,121 | 1,103 | 1,105 | 597 | 69 | 439
|  | % change at CER | 12% | (10%) | (10%) | 50% | 27% | 119% | 86%
| Rare endocrine disorders 3 | 1,923 | 1,334 | 1,323 | 589 | 275 | 34 | 280
| % change at CER | 53% | 48% | 49% | 65% | 44% | 0% | 58%
| Other Rare disease 4 | 384 | 148 | 37 | 236 | 175 | 2 | 59
| % change at CER | 2% | 35% | 102% | (12%) | (17%) | 100% | 5%
| Rare disease total | 5,705 | 2,998 | 2,806 | 2,707 | 1,522 | 187 | 998
| % change at CER | 25% | 18% | 18% | 35% | 15% | 0% | 45%
Total sales | 85,683 | 55,364 | 52,372 | 30,319 | 16,759 | 4,324 | 9,236
| % change at CER | 30% | 29% | 30% | 32% | 32% | 24% | 36%
| % change as reported | 30% | 30% | 31% | 30% | 32% | 27% | 30%
| Share of growth | 100% | 63% | 60% | 37% | 20% | 4% | 13%

1) Primarily NovoNorm®, needles and GlucaGen® HypoKit®.
2) Comprises NovoSeven®, NovoEight®, Esperoct®, Refixia®, NovoThirteen® and Alhemo®.
3) Primarily Norditropin® and Sogroya®.
4) Primarily Vagifem® and Activelle®.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 33 of 35

2024 sales split per area |  |  |  |  |  |  |  |  |
DKK million | Total | North America Operations | The US | International Operations | EMEA | Region China | Rest of World |  |
Diabetes and Obesity care segment |  |  |  |  |  |  |  |  |
| Injectable GLP-1 | 125,824 | 93,083 | 85,900 | 32,741 | 17,423 | 6,737 | 8,581 |  |
| % change at CER | 21% | 27% | 29% | 6% | 6% | 13% | 3% |  |
|  | Ozempic® | 120,342 | 91,287 | 84,201 | 29,055 | 16,001 | 5,762 | 7,292 |  |
|  | % change at CER | 26% | 32% | 34% | 11% | 12% | 22% | 5% |  |
|  | Victoza® | 5,482 | 1,796 | 1,699 | 3,686 | 1,422 | 975 | 1,289 |  |
|  | % change at CER | (36%) | (53%) | (54%) | (23%) | (34%) | (21%) | (7%) |  |
| Rybelsus® | 23,301 | 11,070 | 10,795 | 12,231 | 7,136 | 511 | 4,584 |  |
| % change at CER | 26% | (3)% | (2)% | 69% | 69% | 294% | 60% |  |
| Total GLP-1 | 149,125 | 104,153 | 96,695 | 44,972 | 24,559 | 7,248 | 13,165 |  |
| % change at CER | 22% | 23% | 24% | 18% | 18% | 19% | 18% |  |
| Long-acting insulin | 19,095 | 6,211 | 5,538 | 12,884 | 7,686 | 2,696 | 2,502 |  |
| % change at CER | 30% | 74% | 89% | 16% | 10% | 66% | 0% |  |
|  | Awiqli® | 19 | 4 | — | 15 | 9 | 6 | — |  |
|  | % change at CER | — | — | — | — | — | — | — |  |
|  | Tresiba® | 9,905 | 3,411 | 2,806 | 6,494 | 3,876 | 978 | 1,640 |  |
|  | % change at CER | 29% | 81% | 110% | 13% | 15% | 17% | 7% |  |
|  | Xultophy® | 4,503 | 286 | 281 | 4,217 | 2,185 | 1,414 | 618 |  |
|  | % change at CER | 42% | (14%) | (14%) | 49% | 20% | 251% | 0% |  |
|  | Levemir® | 4,668 | 2,510 | 2,451 | 2,158 | 1,616 | 298 | 244 |  |
|  | % change at CER | 19% | 86% | 92% | (16%) | (11%) | (23%) | (32%) |  |
| Premix insulin | 10,789 | 646 | 632 | 10,143 | 2,637 | 4,784 | 2,722 |  |
| % change at CER | 14% | 178% | 192% | 10% | 3% | 10% | 18% |  |
|  | Ryzodeg® | 4,929 | — | — | 4,929 | 701 | 2,782 | 1,446 |  |
|  | % change at CER | 35% | — | — | 35% | 23% | 44% | 26% |  |
|  | NovoMix® | 5,860 | 646 | 632 | 5,214 | 1,936 | 2,002 | 1,276 |  |
|  | % change at CER | 0% | 178% | 192% | (7%) | (3%) | (18%) | 10% |  |
| Fast-acting insulin | 18,522 | 7,959 | 7,773 | 10,563 | 6,934 | 1,474 | 2,155 |  |
| % change at CER | 16% | 44% | 48% | 2% | 4% | (3%) | (1%) |  |
|  | Fiasp® | 1,869 | 260 | 213 | 1,609 | 1,289 | — | 320 |  |
|  | % change at CER | (14%) | (61%) | (66%) | 7% | 2% | — | 33% |  |
|  | NovoRapid® | 16,653 | 7,699 | 7,560 | 8,954 | 5,645 | 1,474 | 1,835 |  |
|  | % change at CER | 21% | 58% | 63% | 1% | 4% | (3%) | (5%) |  |
| Human insulin | 6,967 | 1,579 | 1,535 | 5,388 | 1,762 | 806 | 2,820 |  |
| % change at CER | (6%) | 8% | 9% | (9%) | (5%) | (33%) | (2%) |  |
| Total insulin | 55,373 | 16,395 | 15,478 | 38,978 | 19,019 | 9,760 | 10,199 |  |
| % change at CER | 17% | 52% | 57% | 6% | 5% | 12% | 3% |  |
| Other Diabetes care 1 | 2,120 | 264 | 213 | 1,856 | 688 | 782 | 386 |  |
| % change at CER | (7%) | (19%) | (20%) | (5%) | 4% | (11%) | (8%) |  |
| Total Diabetes care | 206,618 | 120,812 | 112,386 | 85,806 | 44,266 | 17,790 | 23,750 |  |
| % change at CER | 20% | 26% | 28% | 12% | 12% | 13% | 11% |  |
| Wegovy® | 58,206 | 46,781 | 45,770 | 11,425 | 7,513 | 196 | 3,716 |  |
| % change at CER | 86% | 59% | 55% | — | 291% | — | — |  |
| Saxenda® | 6,940 | 1,377 | 777 | 5,563 | 2,920 | 102 | 2,541 |  |
| % change at CER | (32%) | (64%) | (76%) | (12%) | (22%) | (29%) | 4% |  |
| Total Obesity care | 65,146 | 48,158 | 46,547 | 16,988 | 10,433 | 298 | 6,257 |  |
| % change at CER | 57% | 45% | 42% | 107% | 83% | 108% | 162% |  |
| Diabetes and Obesity care total | 271,764 | 168,970 | 158,933 | 102,794 | 54,699 | 18,088 | 30,007 |  |
| % change at CER | 27% | 31% | 32% | 21% | 21% | 14% | 26% |  |
Rare disease segment |  |  |  |  |  |  |  |  |
| Rare blood disorders 2 | 12,138 | 5,696 | 5,387 | 6,442 | 3,924 | 363 | 2,155 |  |
| % change at CER | 3% | 7% | 6% | 1% | (2%) | (2%) | 7% |  |
|  | Haemophilia A | 2,454 | 548 | 537 | 1,906 | 1,231 | 236 | 439 |  |
|  | % change at CER | 2% | 13% | 15% | (1%) | (3%) | 6% | 0% |  |
|  | Haemophilia B | 1,306 | 657 | 486 | 649 | 436 | 17 | 196 |  |
|  | % change at CER | 24% | 38% | 44% | 12% | 15% | 38% | 4% |  |
|  | NovoSeven® | 7,983 | 4,248 | 4,135 | 3,735 | 2,168 | 110 | 1,457 |  |
|  | % change at CER | 0% | 2% | 2% | (1%) | (5%) | (19%) | 7% |  |
| Rare endocrine disorders 3 | 4,993 | 2,961 | 2,922 | 2,032 | 1,038 | 41 | 953 |  |
| % change at CER | 31% | 65% | 66% | 2% | 48% | (81%) | (11%) |  |
| Other Rare disease 4 | 1,508 | 545 | 160 | 963 | 741 | 9 | 213 |  |
| % change at CER | (2%) | 1% | (21%) | (4%) | (6%) | 80% | 0% |  |
| Rare disease total | 18,639 | 9,202 | 8,469 | 9,437 | 5,703 | 413 | 3,321 |  |
| % change at CER | 9% | 20% | 20% | 0% | 4% | (30%) | 0% |  |
Total sales | 290,403 | 178,172 | 167,402 | 112,231 | 60,402 | 18,501 | 33,328 |  |
| % change at CER | 26% | 30% | 31% | 19% | 19% | 13% | 23% |  |
| % change as reported | 25% | 30% | 31% | 17% | 19% | 11% | 19% |  |
| Share of growth | 100% | 70% | 67% | 30% | 16% | 3% | 11% |  |

1) Primarily NovoNorm®, needles and GlucaGen® HypoKit®.
2) Comprises NovoSeven®, NovoEight®, Esperoct®, Refixia®, NovoThirteen® and Alhemo®.
3) Primarily Norditropin® and Sogroya®.
4) Primarily Vagifem® and Activelle®.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 34 of 35

APPENDIX 7: NON-IFRS FINANCIAL MEASURES (ADDITIONAL INFORMATION)
In this Company Announcement, Novo Nordisk discloses certain financial measures of the Group’s financial performance, financial position and cash flows that reflect adjustments to the directly comparable measures calculated and presented in accordance with IFRS. These non-IFRS financial measures may not be defined and calculated by other companies in the same manner and may thus not be comparable with such measures. The non-IFRS financial measures presented in the Company Announcement are Net sales and operating profit at CER, EBITDA, EBITDA at CER and Free cash flow.
Net sales and operating profit growth at CER
'Growth at CER’ means that the effect of changes in exchange rates is excluded. It is defined as Net sales/Operating profit for the period measured at the average exchange rates for the same period prior year compared with Net sales/Operating profit for the same period prior year. Price adjustments within hyperinflation countries, as defined in IAS 29 ‘Financial reporting in hyperinflation economies’, are excluded from the calculation to avoid growth at CER being artificially inflated.
Growth at CER is considered to be relevant information for investors in order to understand the underlying development in net sales and operating profit by adjusting for the impact of currency fluctuations.

Net sales at CER |  |  |  |  |  |  |  |  |  |
DKK million | 2024 | 2023 | % change 2024 to 2023 |  |  |  |  |  |  |
Net sales | 290,403 | 232,261 |  | 25 | % |  |  |  |  |  |  |
Effect of exchange rates | 1,575 | 7,658 |  |  |  |  |  |  |  |  |
Net sales at CER | 291,978 | 239,919 |  | N/A |  |  |  |  |  |  |
Net sales previous year | 232,261 |  |  |  |  |  |  |  |  |
% increase/(decrease) in constant exchange rates | 26 | % |  |  |  |  |  |  |  |  |
Operating profit at CER |  |  |  |  |  |  |  |  |  |
DKK million | 2024 | 2023 | % change 2024 to 2023 |  |  |  |  |  |  |
Operating profit | 128,339 | 102,574 |  | 25 | % |  |  |  |  |  |  |
Effect of exchange rates | 1,096 | 4,898 |  |  |  |  |  |  |  |  |
Operating profit at CER | 129,435 | 107,472 |  | N/A |  |  |  |  |  |  |
Operating profit previous year | 102,574 |  |  |  |  |  |  |  |  |
% increase/(decrease) in constant exchange rates | 26 | % |  |  |  |  |  |  |  |  |

EBIT DA and EBITDA at CER
Novo Nordisk has significantly increased its Business Development M&A activities and Capital expenditure for property, plant and equipment during recent years. Novo Nordisk defines EBITDA as ’Net profit’ adjusted for 'income taxes', 'financial items', 'depreciation and amortisation' and 'impairment losses and reversals'. EBITDA is a measure that is widely used by investors and analysts as it helps analyse operating results from core business operations without including the effects of capital structure, tax rates and depreciation and amortisation and impairment losses. These factors can vary substantially between companies. 'EBITDA at CER’ means that the effect of changes in exchange rates is excluded by measuring EBITDA (as defined above) at the average exchange rates for the same period prior year.

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

Financial report for the period 1 January 2024 to 31 December 2024 | Page 35 of 35

EBITDA and EBITDA at CER |  |  |  |  |  |  |  |  |  |
DKK million | 2024 | 2023 | % change 2024 to 2023 |  |  |  |  |  |  |
Net profit | 100,988 | 83,683 |  | 21 | % |  |  |  |  |  |  |
Income taxes | 26,203 | 20,991 |  | 25 | % |  |  |  |  |  |  |
Financial income | (6,198) | (2,945) |  | 110 | % |  |  |  |  |  |  |
Financial expenses | 7,346 | 845 |  | 769 | % |  |  |  |  |  |  |
Operating profit (EBIT) | 128,339 | 102,574 |  | 25 | % |  |  |  |  |  |  |
Depreciation, amortisation, impairment losses and reversals | 19,107 | 9,413 |  | 103 | % |  |  |  |  |  |  |
EBITDA | 147,446 | 111,987 |  | 32 | % |  |  |  |  |  |  |
Effect of exchange rates | 1,146 | 5,043 |  |  |  |  |  |  |  |  |
EBITDA at CER | 148,592 | 117,030 |  | N/A |  |  |  |  |  |  |
EBITDA previous year | 111,987 |  |  |  |  |  |  |  |  |
% increase/(decrease) in constant exchange rates | 33 | % |  |  |  |  |  |  |  |  |

Free cash flow
Novo Nordisk defines free cash flow as ’net cash generated from operating activities’, less ‘net cash used in investing activities’, less repayment on lease liabilities and excluding net change of marketable securities. Free cash flow is a measure of the amount of cash generated in the period which is available for the Board of Directors to allocate between Novo Nordisk's capital providers, through e.g. dividends, share repurchas es and repayment of debt (excluding lease liability repayments) or for retaining in the business to fund future growth.
The following table shows a reconciliation of Free cash flow with Net cash generated from operating activities, the most directly comparable IFRS financial measure:

Free cash flow |  |  |  |  |  |
DKK million | 2024 | 2023 |  |  |  |
Net cash generated from operating activities | 120,968 |  | 108,908 |  |  |  |  |
Net cash used in investing activities | (128,895) |  | (43,892) |  |  |  |  |
Net purchase of marketable securities | (5,363) |  | 4,758 |  |  |  |  |
Repayment on lease liabilities | (1,417) |  | (1,448) |  |  |  |  |
Free cash flow | (14,707) |  | 68,326 |  |  |  |  |

| Strategic aspirations | Performance highlights | Commercial execution | Financials | Cash flow and capital allocation | Outlook | Innovation and therapeutic focus | Purpose and sustainability | Legal | Financial Information
|  |  |  |  | Company announcement No 7 / 2025

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: February 5, 2025
Novo Nordisk A/S
Lars Fruergaard Jørgensen
Chief Executive Officer